

Disclaimer

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description FDA requested use of Modular Program #3 to investigate hemolysis events (see Appendix B) following new use of several Ig products (see Appendix A) with varying follow-up periods based on last date of exposure for each episode (exposure extension period). Users were excluded if evidence of use of another product listed in Appendix A was found in the 28 days before, the day of, or the 28 days after index use of the exposure of interest. In addition, the Charlson Comorbidity Index module was used. Two runs were executed to analyze two different age cohorts: one with all age groups, and a second with the 0-17 age group excluded. In total, 80 different scenarios (see Specifications - the 40 scenarios run twice with the different age groupings) were examined in this request with differing exposures and exposure extension periods. The time window for the request was January 1, 2006 to December 31, 2012. The package was distributed to 18 Data Partners on January 28, 2014. Please see the Specifications tab for more details on each scenario. This report provides results for the second run of the program, where the age groupings include 18-44, 45-64, 65+ years.

Request ID to09y05_mpr_wp14_v03 - report 2 of 2

Specifications Program parameter inputs and scenarios

Glossary List of Terms found in this Report and their Definitions

Table 1 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, New Episodes with Events, Number of Events, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Dispensings per User, New Episodes with Events per 1,000 Years at Risk, and Number of Events per 1,000 Years at Risk by Drug Product and Episode Extension Period*

Table 2 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, New Episodes with Events, Number of Events, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Dispensings per User, New Episodes with Events per 1,000 Years at Risk, and Number of Events per 1,000 Years at Risk by Drug Product, Episode Extension Period and Age Group*

Table 3 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, New Episodes with Events, Number of Events, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Dispensings per User, New Episodes with Events per 1,000 Years at Risk, and Number of Events per 1,000 Years at Risk by Drug Product, Episode Extension Period and Sex*

Table 4 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, New Episodes with Events, Number of Events, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Dispensings per User, New Episodes with Events per 1,000 Years at Risk, and Number of Events per 1,000 Years at Risk by Drug Product, Episode Extension Period and Year*

Table 5 Table displaying the Number of New Users, New Episodes, Dispensings, Total Days Supplied, New Episodes with Events, Number of Events, Years at Risk, Eligible Members, Member-Years, New Users per 100,000 Eligible Members, Dispensings per User, New Episodes with Events per 1,000 Years at Risk, and Number of Events per 1,000 Years at Risk by Drug Product, Episode Extension Period and Pre-Index Charlson Comorbidity Index (CCI) Score*

Appendix A List of exposure drug codes

Appendix B List of event diagnosis codes

Notes: * Dispensings = Days Supplied = Amount Supplied since the exposures are procedure codes. Therefore, Days Supplied, Amount Supplied, and associated rates are omitted from the tables.

Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

to09y05_mpr_wp14_v03 Specifications

Modular Program #3 was used to investigate hemolysis events (see Appendix B) following new use of several Ig products (see Appendix A) with varying follow-up periods based on last date of exposure for each episode (exposure extension period). Users were excluded if evidence of use of another product listed in Appendix A was found in the 28 days before, the day of, or the 28 days after index use of the exposure of interest. In addition, the Charlson Comorbidity Index module was used. Two runs were executed to analyze two different age cohorts: one with all age groups and the second excluding the 0-17 age group. In total, 80 different scenarios (the 40 below run twice with the different age groupings) were examined in this report with differing exposures and exposure extension periods. See below for a description of each of these scenarios.

Coverage Requirement Drug and Medical Coverage
Query Period January 1, 2006 to December 31, 2012
Enrollment Gap 45 Days
Enrollment Days 183
Age Stratifications Run 1: 0-17, 18-44, 45-64, 65+
 Run 2: 18-44, 45-64, 65+
Minimum Days Supplied and 0 Days

Scenario	Drug/Exposure			Exposure			Cohort Definition	Inclusion/ Exclusion	Exclusion Criteria		Care Setting PDX	Event/Outcome				Charlson Comorbidity Index (CCI)					
	Incident exposure	Incident w/ respect to:	Exposure	Episode Gap	Extension Period	Washout (days)			Lookback Start	Lookback End		Event/ Outcome	Incident w/ respect to:	Washout (days)	Event De- duplication	Care Setting PDX	Blackout Period	CCI Group Stratification	Number of Pre-Index Days	Number of Index Days	Include Index Days
1	Flebogamma	Flebogamma		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
2	Gammagard Liquid	Gammagard Liquid		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
3	Gammaplex	Gammaplex		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
4	Gamunex	Gamunex		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
5	Octagam	Octagam		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
6	Privigen	Privigen		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
7	Lyophilized product IV	Lyophilized product IV		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
8	Non-lyophilized intramuscular route	Non-lyophilized intramuscular route		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
9	Non-lyophilized unspecified route	Non-lyophilized unspecified route		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
10	Other IVIg, brand not specified	Other IVIg, brand not specified		2	3	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
11	Flebogamma	Flebogamma		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
12	Gammagard Liquid	Gammagard Liquid		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
13	Gammaplex	Gammaplex		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
14	Gamunex	Gamunex		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
15	Octagam	Octagam		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
16	Privigen	Privigen		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
17	Lyophilized product IV	Lyophilized product IV		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
18	Non-lyophilized intramuscular route	Non-lyophilized intramuscular route		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
19	Non-lyophilized unspecified route	Non-lyophilized unspecified route		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
20	Other IVIg, brand not specified	Other IVIg, brand not specified		2	14	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
21	Flebogamma	Flebogamma		2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
22	Gammagard Liquid	Gammagard Liquid		2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0

Drug/Exposure							Exclusion Criteria				Event/Outcome						Charlson Comorbidity Index (CCI)				
Scenario	Incident exposure		Incident w/ respect to:	Exposure			Cohort Definition	Inclusion/ Exclusion	Lookback Start	Lookback End	Care Setting PDX	Event/ Outcome	Incident w/ respect to:	Washout (days)	Event De-duplication	Care Setting PDX	Blackout Period	CCI Group Stratification	Number of		
				Episode Gap	Extension Period	Washout (days)													Pre-Index Days	Number of Index Days	Include Index Days
23	Gammaplex		Gammaplex	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
24	Gamunex		Gamunex	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
25	Octagam		Octagam	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
26	Privigen		Privigen	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
27	Lyophilized product IV		Lyophilized product IV	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
28	Non-lyophilized intramuscular route		Non-lyophilized intramuscular route	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
29	Non-lyophilized unspecified route		Non-lyophilized unspecified route	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
30	Other IVIg, brand not specified		Other IVIg, brand not specified	2	21	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
31	Flebogamma		Flebogamma	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
32	Gammagard Liquid		Gammagard Liquid	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
33	Gammaplex		Gammaplex	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
34	Gamunex		Gamunex	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
35	Octagam		Octagam	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
36	Privigen		Privigen	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
37	Lyophilized product IV		Lyophilized product IV	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
38	Non-lyophilized intramuscular route		Non-lyophilized intramuscular route	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
39	Non-lyophilized unspecified route		Non-lyophilized unspecified route	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0
40	Other IVIg, brand not specified		Other IVIg, brand not specified	2	28	28	02	All specified Ig except exposure of interest	-28	28	IP, ED, OA, AV	Hemolysis	Hemolysis	90	2	IP*, ED*, OA*, AV*	0	0, 1, 2, 3-4, 5-6, 7+	365	0	0

All exposure, event, and pre-existing condition codes provided by FDA requester.

Glossary of Terms in Modular Program 3*

- Amount Supplied** - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing. This is equivalent to the "RxAmt"
- Blackout Period** - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
- Care Setting** - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other
- Cohort Definition (drug/exposure)**- Indicates how the cohort will be defined: (1) 01: Cohort includes only the first valid incident treatment episode during the query period; (2) 02: Cohort includes all valid incident treatment episodes during the query period; (3) 03: Cohort includes all valid incident treatment episodes during the query period until an event occurs
- Days Supplied** - number of days supplied for all dispensings in qualifying treatment episodes.
- Years at Risk** - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.
- Eligible Members** - Number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
- Enrollment Gap** - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled"
- Episode Gap** - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same
- Event Deduplication** - specifies how events are counted by the MP algorithm: A value of 0 counts all occurrences of an event group code of interest; a value of 1 de-duplicates occurrences of the same event code on the same day (i.e., de-duplicates at the exact match code level); and a value of 2 de-duplicates occurrences of the same event group code on the same day (e.g., de-duplicates at the GROUP level).
- Exposure Extension Period** - number of days post treatment period in which the outcomes/events are counted for a treatment episode.
- Lookback Period (pre-existing condition)** - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).
- Member-Years** - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout
- Minimum Days Supplied** - specifies a minimum number of days in length of the days supplied for the episode to be considered
- Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered
- New Episodes** - new treatment episodes; length of episode is determined by days supplied in one dispensing (or consecutive dispensings
- New Episodes with Events** - number of unique episodes during which at least one incident event occurs. Each episode may only be counted
- New Users** - number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.
- Number of Events** - total number of incident events. An individual or a treatment episode can have more than one incident event provided that the incident event meets the event incidence criteria.
- Principal Diagnosis (PDX)** - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. YES will only consider diagnoses flagged as Principal
- Query Period** - period in which the modular program looks for exposures and outcomes of interest.
- Treatment Episode Truncation Indicator** - indicates whether observation of the incident query code during follow-up requires truncation of valid treatment episodes. A value of Y indicates that the treatment episodes should be truncated at the first occurrence of an incident query code. A value of N indicates that the treatment episodes should not be truncated at the occurrence of the incident query code.
- Washout Period (drug/exposure)**** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
- Washout Period (event/outcome)**** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1. Summary of Incident Ig Use and Hemolysis in the MSDD between January 1, 2006 and December 31, 2012, by Ig Product and Episode Extension Period

	New Users	New Episodes	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Flebogamma												
<i>3 day episode extension</i>	1,872	6,180	7,740	72.4	9	11	67,678,049	149,480,160.5	2.77	4.13	124.30	151.92
<i>14 day episode extension</i>	1,872	6,180	7,740	255.3	14	16	67,678,049	149,480,160.5	2.77	4.13	54.83	62.66
<i>21 day episode extension</i>	1,872	6,180	7,740	369.2	16	18	67,678,049	149,480,160.5	2.77	4.13	43.34	48.75
<i>28 day episode extension</i>	1,872	6,180	7,740	472.7	20	23	67,678,049	149,480,160.5	2.77	4.13	42.31	48.65
Gammagard Liquid												
<i>3 day episode extension</i>	8,294	32,176	37,215	369.5	24	31	67,678,795	149,480,310.5	12.25	4.49	64.96	83.90
<i>14 day episode extension</i>	8,294	32,176	37,215	1,319.3	35	50	67,678,795	149,480,310.5	12.25	4.49	26.53	37.90
<i>21 day episode extension</i>	8,294	32,176	37,215	1,906.6	43	78	67,678,795	149,480,310.5	12.25	4.49	22.55	40.91
<i>28 day episode extension</i>	8,294	32,176	37,215	2,428.8	51	98	67,678,795	149,480,310.5	12.25	4.49	21.00	40.35
Gammaplex												
<i>3 day episode extension</i>	50	120	156	1.4	0	0	67,677,903	149,479,924.2	0.07	3.12	0.00	0.00
<i>14 day episode extension</i>	50	120	156	5.0	0	0	67,677,903	149,479,924.2	0.07	3.12	0.00	0.00
<i>21 day episode extension</i>	50	120	156	7.2	0	0	67,677,903	149,479,924.2	0.07	3.12	0.00	0.00
<i>28 day episode extension</i>	50	120	156	9.2	0	0	67,677,903	149,479,924.2	0.07	3.12	0.00	0.00
Gamunex												
<i>3 day episode extension</i>	5,568	21,890	26,073	253.2	7	7	67,678,483	149,479,488.2	8.23	4.68	27.64	27.64
<i>14 day episode extension</i>	5,568	21,890	26,073	899.7	15	20	67,678,483	149,479,488.2	8.23	4.68	16.67	22.23
<i>21 day episode extension</i>	5,568	21,890	26,073	1,297.5	25	36	67,678,483	149,479,488.2	8.23	4.68	19.27	27.75
<i>28 day episode extension</i>	5,568	21,890	26,073	1,649.6	29	50	67,678,483	149,479,488.2	8.23	4.68	17.58	30.31
Octagam												
<i>3 day episode extension</i>	2,050	6,982	8,091	80.4	9	17	67,678,202	149,480,261.5	3.03	3.95	111.90	211.37
<i>14 day episode extension</i>	2,050	6,982	8,091	287.1	13	32	67,678,202	149,480,261.5	3.03	3.95	45.28	111.47
<i>21 day episode extension</i>	2,050	6,982	8,091	415.5	15	41	67,678,202	149,480,261.5	3.03	3.95	36.10	98.68
<i>28 day episode extension</i>	2,050	6,982	8,091	531.4	15	46	67,678,202	149,480,261.5	3.03	3.95	28.23	86.57
Privigen												
<i>3 day episode extension</i>	2,921	9,494	11,533	110.4	10	14	67,678,170	149,479,748.4	4.32	3.95	90.59	126.82
<i>14 day episode extension</i>	2,921	9,494	11,533	390.9	14	23	67,678,170	149,479,748.4	4.32	3.95	35.81	58.83
<i>21 day episode extension</i>	2,921	9,494	11,533	564.6	14	28	67,678,170	149,479,748.4	4.32	3.95	24.80	49.59
<i>28 day episode extension</i>	2,921	9,494	11,533	719.7	17	35	67,678,170	149,479,748.4	4.32	3.95	23.62	48.63

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Lyophilized product IV													
<i>3 day episode extension</i>	5,165	19,228	23,058	23,058	222.7	23	25	67,678,503	149,480,642.8	7.63	4.46	103.29	112.27
<i>14 day episode extension</i>	5,165	19,228	23,058	23,058	791.5	31	35	67,678,503	149,480,642.8	7.63	4.46	39.17	44.22
<i>21 day episode extension</i>	5,165	19,228	23,058	23,058	1,143.8	33	41	67,678,503	149,480,642.8	7.63	4.46	28.85	35.84
<i>28 day episode extension</i>	5,165	19,228	23,058	23,058	1,459.7	37	48	67,678,503	149,480,642.8	7.63	4.46	25.35	32.88
Non-lyophilized intramuscular route													
<i>3 day episode extension</i>	5,843	8,649	8,724	8,724	95.1	1	1	67,678,705	149,496,082.7	8.63	1.49	10.51	10.51
<i>14 day episode extension</i>	5,843	8,649	8,724	8,724	351.6	1	1	67,678,705	149,496,082.7	8.63	1.49	2.84	2.84
<i>21 day episode extension</i>	5,843	8,649	8,724	8,724	510.6	1	1	67,678,705	149,496,082.7	8.63	1.49	1.96	1.96
<i>28 day episode extension</i>	5,843	8,649	8,724	8,724	662.9	1	1	67,678,705	149,496,082.7	8.63	1.49	1.51	1.51
Non-lyophilized unspecified route													
<i>3 day episode extension</i>	7,907	10,215	10,383	10,383	111.4	138	163	67,679,124	149,492,348.9	11.68	1.31	1239.11	1463.59
<i>14 day episode extension</i>	7,907	10,215	10,383	10,383	411.8	152	252	67,679,124	149,492,348.9	11.68	1.31	369.15	612.01
<i>21 day episode extension</i>	7,907	10,215	10,383	10,383	598.1	162	305	67,679,124	149,492,348.9	11.68	1.31	270.88	509.99
<i>28 day episode extension</i>	7,907	10,215	10,383	10,383	779.6	168	351	67,679,124	149,492,348.9	11.68	1.31	215.49	450.23
Other IVig, brand not specified													
<i>3 day episode extension</i>	2,849	6,915	8,240	8,240	80.1	4	6	67,678,341	149,481,573.5	4.21	2.89	49.91	74.86
<i>14 day episode extension</i>	2,849	6,915	8,240	8,240	282.3	9	15	67,678,341	149,481,573.5	4.21	2.89	31.88	53.13
<i>21 day episode extension</i>	2,849	6,915	8,240	8,240	406.0	10	19	67,678,341	149,481,573.5	4.21	2.89	24.63	46.79
<i>28 day episode extension</i>	2,849	6,915	8,240	8,240	516.8	13	22	67,678,341	149,481,573.5	4.21	2.89	25.15	42.57

Table 2. Summary of Incident Ig Use and Hemolysis in the MSDD between January 1, 2006 and December 31, 2012, by Ig Product, Episode Extension Period, and Age Group

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Flebogamma													
<i>3 day episode extension</i>													
18 to 44 Years	385	1,103	1,422	1,422	13.1	1	1	38,897,907	70,364,592.9	0.99	3.69	76.40	76.40
45 to 64 Years	855	2,610	3,266	3,266	30.6	3	4	25,226,433	57,813,091.6	3.39	3.82	98.06	130.75
65+ Years	661	2,467	3,052	3,052	28.7	5	6	7,844,178	21,302,476.0	8.43	4.62	174.08	208.89
<i>14 day episode extension</i>													
18 to 44 Years	385	1,103	1,422	1,422	45.5	2	2	38,897,907	70,364,592.9	0.99	3.69	43.96	43.96
45 to 64 Years	855	2,610	3,266	3,266	107.6	5	6	25,226,433	57,813,091.6	3.39	3.82	46.46	55.75
65+ Years	661	2,467	3,052	3,052	102.2	7	8	7,844,178	21,302,476.0	8.43	4.62	68.49	78.28
<i>21 day episode extension</i>													
18 to 44 Years	385	1,103	1,422	1,422	65.4	3	3	38,897,907	70,364,592.9	0.99	3.69	45.89	45.89
45 to 64 Years	855	2,610	3,266	3,266	155.6	5	6	25,226,433	57,813,091.6	3.39	3.82	32.13	38.56
65+ Years	661	2,467	3,052	3,052	148.2	8	9	7,844,178	21,302,476.0	8.43	4.62	53.97	60.71
<i>28 day episode extension</i>													
18 to 44 Years	385	1,103	1,422	1,422	82.7	3	4	38,897,907	70,364,592.9	0.99	3.69	36.28	48.38
45 to 64 Years	855	2,610	3,266	3,266	199.4	6	7	25,226,433	57,813,091.6	3.39	3.82	30.08	35.10
65+ Years	661	2,467	3,052	3,052	190.6	11	12	7,844,178	21,302,476.0	8.43	4.62	57.71	62.96
Gammagard Liquid													
<i>3 day episode extension</i>													
18 to 44 Years	2,234	7,764	8,880	8,880	89.0	6	6	38,898,202	70,364,721.0	5.74	3.97	67.41	67.41
45 to 64 Years	4,153	16,370	18,900	18,900	187.9	8	14	25,226,865	57,813,143.6	16.46	4.55	42.58	74.52
65+ Years	2,091	8,042	9,435	9,435	92.6	10	11	7,844,330	21,302,445.8	26.66	4.51	108.00	118.81
<i>14 day episode extension</i>													
18 to 44 Years	2,234	7,764	8,880	8,880	317.2	8	10	38,898,202	70,364,721.0	5.74	3.97	25.22	31.52
45 to 64 Years	4,153	16,370	18,900	18,900	670.5	14	25	25,226,865	57,813,143.6	16.46	4.55	20.88	37.29
65+ Years	2,091	8,042	9,435	9,435	331.6	13	15	7,844,330	21,302,445.8	26.66	4.51	39.21	45.24
<i>21 day episode extension</i>													
18 to 44 Years	2,234	7,764	8,880	8,880	457.4	9	19	38,898,202	70,364,721.0	5.74	3.97	19.68	41.54
45 to 64 Years	4,153	16,370	18,900	18,900	968.5	17	36	25,226,865	57,813,143.6	16.46	4.55	17.55	37.17
65+ Years	2,091	8,042	9,435	9,435	480.7	17	23	7,844,330	21,302,445.8	26.66	4.51	35.37	47.85

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
18 to 44 Years	2,234	7,764	8,880	8,880	579.6	9	28	38,898,202	70,364,721.0	5.74	3.97	15.53	48.31
45 to 64 Years	4,153	16,370	18,900	18,900	1,233.3	19	39	25,226,865	57,813,143.6	16.46	4.55	15.41	31.62
65+ Years	2,091	8,042	9,435	9,435	615.9	23	31	7,844,330	21,302,445.8	26.66	4.51	37.34	50.33
Gammaplex													
3 day episode extension													
18 to 44 Years	13	27	36	36	0.3	0	0	38,897,868	70,364,474.3	0.03	2.77	0.00	0.00
45 to 64 Years	25	63	88	88	0.8	0	0	25,226,347	57,813,016.3	0.10	3.52	0.00	0.00
65+ Years	13	30	32	32	0.3	0	0	7,844,125	21,302,433.5	0.17	2.46	0.00	0.00
14 day episode extension													
18 to 44 Years	13	27	36	36	1.1	0	0	38,897,868	70,364,474.3	0.03	2.77	0.00	0.00
45 to 64 Years	25	63	88	88	2.6	0	0	25,226,347	57,813,016.3	0.10	3.52	0.00	0.00
65+ Years	13	30	32	32	1.2	0	0	7,844,125	21,302,433.5	0.17	2.46	0.00	0.00
21 day episode extension													
18 to 44 Years	13	27	36	36	1.6	0	0	38,897,868	70,364,474.3	0.03	2.77	0.00	0.00
45 to 64 Years	25	63	88	88	3.8	0	0	25,226,347	57,813,016.3	0.10	3.52	0.00	0.00
65+ Years	13	30	32	32	1.8	0	0	7,844,125	21,302,433.5	0.17	2.46	0.00	0.00
28 day episode extension													
18 to 44 Years	13	27	36	36	2.0	0	0	38,897,868	70,364,474.3	0.03	2.77	0.00	0.00
45 to 64 Years	25	63	88	88	4.9	0	0	25,226,347	57,813,016.3	0.10	3.52	0.00	0.00
65+ Years	13	30	32	32	2.4	0	0	7,844,125	21,302,433.5	0.17	2.46	0.00	0.00
Gamunex													
3 day episode extension													
18 to 44 Years	1,496	5,299	6,246	6,246	61.1	1	1	38,898,074	70,364,494.3	3.85	4.18	16.36	16.36
45 to 64 Years	2,896	11,698	13,981	13,981	135.4	5	5	25,226,679	57,812,649.6	11.48	4.83	36.92	36.92
65+ Years	1,348	4,893	5,846	5,846	56.7	1	1	7,844,252	21,302,344.3	17.18	4.34	17.64	17.64
14 day episode extension													
18 to 44 Years	1,496	5,299	6,246	6,246	216.9	5	6	38,898,074	70,364,494.3	3.85	4.18	23.06	27.67
45 to 64 Years	2,896	11,698	13,981	13,981	480.7	9	13	25,226,679	57,812,649.6	11.48	4.83	18.72	27.04
65+ Years	1,348	4,893	5,846	5,846	202.2	1	1	7,844,252	21,302,344.3	17.18	4.34	4.95	4.95

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
21 day episode extension													
18 to 44 Years	1,496	5,299	6,246	6,246	312.1	8	9	38,898,074	70,364,494.3	3.85	4.18	25.63	28.84
45 to 64 Years	2,896	11,698	13,981	13,981	692.5	14	24	25,226,679	57,812,649.6	11.48	4.83	20.22	34.66
65+ Years	1,348	4,893	5,846	5,846	292.9	3	3	7,844,252	21,302,344.3	17.18	4.34	10.24	10.24
28 day episode extension													
18 to 44 Years	1,496	5,299	6,246	6,246	395.0	9	13	38,898,074	70,364,494.3	3.85	4.18	22.78	32.91
45 to 64 Years	2,896	11,698	13,981	13,981	879.4	17	33	25,226,679	57,812,649.6	11.48	4.83	19.33	37.53
65+ Years	1,348	4,893	5,846	5,846	375.2	3	4	7,844,252	21,302,344.3	17.18	4.34	8.00	10.66
Octagam													
3 day episode extension													
18 to 44 Years	478	1,623	1,952	1,952	19.1	3	4	38,897,937	70,364,572.2	1.23	4.08	157.37	209.82
45 to 64 Years	1,029	3,562	4,061	4,061	40.8	1	5	25,226,537	57,813,136.0	4.08	3.95	24.50	122.50
65+ Years	584	1,797	2,078	2,078	20.5	5	8	7,844,208	21,302,553.3	7.44	3.56	243.34	389.34
14 day episode extension													
18 to 44 Years	478	1,623	1,952	1,952	66.6	4	16	38,897,937	70,364,572.2	1.23	4.08	60.09	240.35
45 to 64 Years	1,029	3,562	4,061	4,061	146.7	4	8	25,226,537	57,813,136.0	4.08	3.95	27.27	54.55
65+ Years	584	1,797	2,078	2,078	73.9	5	8	7,844,208	21,302,553.3	7.44	3.56	67.70	108.31
21 day episode extension													
18 to 44 Years	478	1,623	1,952	1,952	95.8	5	23	38,897,937	70,364,572.2	1.23	4.08	52.18	240.01
45 to 64 Years	1,029	3,562	4,061	4,061	212.4	4	9	25,226,537	57,813,136.0	4.08	3.95	18.83	42.37
65+ Years	584	1,797	2,078	2,078	107.2	6	9	7,844,208	21,302,553.3	7.44	3.56	55.96	83.93
28 day episode extension													
18 to 44 Years	478	1,623	1,952	1,952	122.1	5	27	38,897,937	70,364,572.2	1.23	4.08	40.95	221.12
45 to 64 Years	1,029	3,562	4,061	4,061	271.8	4	9	25,226,537	57,813,136.0	4.08	3.95	14.72	33.11
65+ Years	584	1,797	2,078	2,078	137.5	6	10	7,844,208	21,302,553.3	7.44	3.56	43.65	72.75
Privigen													
3 day episode extension													
18 to 44 Years	752	2,165	2,601	2,601	25.1	0	0	38,897,951	70,364,520.6	1.93	3.46	0.00	0.00
45 to 64 Years	1,386	4,520	5,518	5,518	52.6	5	5	25,226,498	57,812,945.2	5.49	3.98	95.07	95.07
65+ Years	831	2,809	3,414	3,414	32.7	5	9	7,844,187	21,302,282.6	10.59	4.11	153.11	275.59

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
14 day episode extension													
18 to 44 Years	752	2,165	2,601	2,601	88.7	0	0	38,897,951	70,364,520.6	1.93	3.46	0.00	0.00
45 to 64 Years	1,386	4,520	5,518	5,518	186.2	8	12	25,226,498	57,812,945.2	5.49	3.98	42.96	64.45
65+ Years	831	2,809	3,414	3,414	116.1	6	11	7,844,187	21,302,282.6	10.59	4.11	51.70	94.79
21 day episode extension													
18 to 44 Years	752	2,165	2,601	2,601	128.0	0	0	38,897,951	70,364,520.6	1.93	3.46	0.00	0.00
45 to 64 Years	1,386	4,520	5,518	5,518	268.8	8	17	25,226,498	57,812,945.2	5.49	3.98	29.77	63.25
65+ Years	831	2,809	3,414	3,414	167.8	6	11	7,844,187	21,302,282.6	10.59	4.11	35.75	65.54
28 day episode extension													
18 to 44 Years	752	2,165	2,601	2,601	162.8	1	1	38,897,951	70,364,520.6	1.93	3.46	6.14	6.14
45 to 64 Years	1,386	4,520	5,518	5,518	342.5	9	22	25,226,498	57,812,945.2	5.49	3.98	26.27	64.23
65+ Years	831	2,809	3,414	3,414	214.4	7	12	7,844,187	21,302,282.6	10.59	4.11	32.66	55.98
Lyophilized product IV													
3 day episode extension													
18 to 44 Years	1,333	4,549	5,430	5,430	52.7	3	3	38,898,071	70,364,508.5	3.43	4.07	56.91	56.91
45 to 64 Years	2,488	9,271	11,267	11,267	107.9	7	7	25,226,696	57,813,233.7	9.86	4.53	64.90	64.90
65+ Years	1,473	5,408	6,361	6,361	62.1	13	15	7,844,308	21,302,900.6	18.78	4.32	209.31	241.51
14 day episode extension													
18 to 44 Years	1,333	4,549	5,430	5,430	187.0	5	5	38,898,071	70,364,508.5	3.43	4.07	26.74	26.74
45 to 64 Years	2,488	9,271	11,267	11,267	382.3	8	8	25,226,696	57,813,233.7	9.86	4.53	20.93	20.93
65+ Years	1,473	5,408	6,361	6,361	222.3	18	22	7,844,308	21,302,900.6	18.78	4.32	80.99	98.99
21 day episode extension													
18 to 44 Years	1,333	4,549	5,430	5,430	269.7	5	5	38,898,071	70,364,508.5	3.43	4.07	18.54	18.54
45 to 64 Years	2,488	9,271	11,267	11,267	552.4	9	12	25,226,696	57,813,233.7	9.86	4.53	16.29	21.72
65+ Years	1,473	5,408	6,361	6,361	321.8	19	24	7,844,308	21,302,900.6	18.78	4.32	59.05	74.59
28 day episode extension													
18 to 44 Years	1,333	4,549	5,430	5,430	342.6	6	6	38,898,071	70,364,508.5	3.43	4.07	17.51	17.51
45 to 64 Years	2,488	9,271	11,267	11,267	704.3	9	13	25,226,696	57,813,233.7	9.86	4.53	12.78	18.46
65+ Years	1,473	5,408	6,361	6,361	412.8	22	29	7,844,308	21,302,900.6	18.78	4.32	53.29	70.25

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Non-lyophilized intramuscular route													
<i>3 day episode extension</i>													
18 to 44 Years	2,395	3,066	3,083	3,083	33.7	1	1	38,898,370	70,370,241.7	6.16	1.29	29.71	29.71
45 to 64 Years	2,752	4,299	4,325	4,325	47.2	0	0	25,226,959	57,820,908.5	10.91	1.57	0.00	0.00
65+ Years	737	1,284	1,316	1,316	14.2	0	0	7,844,490	21,304,932.5	9.40	1.79	0.00	0.00
<i>14 day episode extension</i>													
18 to 44 Years	2,395	3,066	3,083	3,083	124.8	1	1	38,898,370	70,370,241.7	6.16	1.29	8.01	8.01
45 to 64 Years	2,752	4,299	4,325	4,325	174.3	0	0	25,226,959	57,820,908.5	10.91	1.57	0.00	0.00
65+ Years	737	1,284	1,316	1,316	52.5	0	0	7,844,490	21,304,932.5	9.40	1.79	0.00	0.00
<i>21 day episode extension</i>													
18 to 44 Years	2,395	3,066	3,083	3,083	181.6	1	1	38,898,370	70,370,241.7	6.16	1.29	5.51	5.51
45 to 64 Years	2,752	4,299	4,325	4,325	252.6	0	0	25,226,959	57,820,908.5	10.91	1.57	0.00	0.00
65+ Years	737	1,284	1,316	1,316	76.4	0	0	7,844,490	21,304,932.5	9.40	1.79	0.00	0.00
<i>28 day episode extension</i>													
18 to 44 Years	2,395	3,066	3,083	3,083	236.5	1	1	38,898,370	70,370,241.7	6.16	1.29	4.23	4.23
45 to 64 Years	2,752	4,299	4,325	4,325	327.1	0	0	25,226,959	57,820,908.5	10.91	1.57	0.00	0.00
65+ Years	737	1,284	1,316	1,316	99.4	0	0	7,844,490	21,304,932.5	9.40	1.79	0.00	0.00
Non-lyophilized unspecified route													
<i>3 day episode extension</i>													
18 to 44 Years	2,951	3,672	3,738	3,738	40.1	42	55	38,898,574	70,369,154.1	7.59	1.27	1047.06	1371.15
45 to 64 Years	3,055	4,026	4,112	4,112	44.0	52	58	25,226,880	57,817,483.2	12.11	1.35	1182.41	1318.84
65+ Years	1,918	2,517	2,533	2,533	27.3	44	50	7,844,451	21,305,711.5	24.45	1.32	1612.91	1832.85
<i>14 day episode extension</i>													
18 to 44 Years	2,951	3,672	3,738	3,738	148.2	46	78	38,898,574	70,369,154.1	7.59	1.27	310.37	526.28
45 to 64 Years	3,055	4,026	4,112	4,112	162.2	58	102	25,226,880	57,817,483.2	12.11	1.35	357.59	628.87
65+ Years	1,918	2,517	2,533	2,533	101.3	48	72	7,844,451	21,305,711.5	24.45	1.32	473.61	710.41
<i>21 day episode extension</i>													
18 to 44 Years	2,951	3,672	3,738	3,738	215.5	50	94	38,898,574	70,369,154.1	7.59	1.27	231.97	436.10
45 to 64 Years	3,055	4,026	4,112	4,112	235.5	62	125	25,226,880	57,817,483.2	12.11	1.35	263.31	530.87
65+ Years	1,918	2,517	2,533	2,533	147.0	50	86	7,844,451	21,305,711.5	24.45	1.32	340.03	584.85

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
18 to 44 Years	2,951	3,672	3,738	3,738	281.9	51	101	38,898,574	70,369,154.1	7.59	1.27	180.89	358.23
45 to 64 Years	3,055	4,026	4,112	4,112	306.8	65	145	25,226,880	57,817,483.2	12.11	1.35	211.85	472.59
65+ Years	1,918	2,517	2,533	2,533	190.8	52	105	7,844,451	21,305,711.5	24.45	1.32	272.48	550.19
Other IVIg, brand not specified													
3 day episode extension													
18 to 44 Years	870	1,970	2,289	2,289	22.7	2	2	38,898,038	70,365,108.1	2.24	2.63	88.13	88.13
45 to 64 Years	1,387	3,486	4,227	4,227	40.6	2	4	25,226,600	57,813,690.4	5.50	3.05	49.27	98.55
65+ Years	624	1,459	1,724	1,724	16.9	0	0	7,844,233	21,302,774.9	7.95	2.76	0.00	0.00
14 day episode extension													
18 to 44 Years	870	1,970	2,289	2,289	80.2	3	4	38,898,038	70,365,108.1	2.24	2.63	37.39	49.86
45 to 64 Years	1,387	3,486	4,227	4,227	142.3	4	9	25,226,600	57,813,690.4	5.50	3.05	28.11	63.25
65+ Years	624	1,459	1,724	1,724	59.8	2	2	7,844,233	21,302,774.9	7.95	2.76	33.45	33.45
21 day episode extension													
18 to 44 Years	870	1,970	2,289	2,289	115.3	3	5	38,898,038	70,365,108.1	2.24	2.63	26.01	43.35
45 to 64 Years	1,387	3,486	4,227	4,227	204.4	4	10	25,226,600	57,813,690.4	5.50	3.05	19.57	48.92
65+ Years	624	1,459	1,724	1,724	86.3	3	4	7,844,233	21,302,774.9	7.95	2.76	34.78	46.38
28 day episode extension													
18 to 44 Years	870	1,970	2,289	2,289	146.1	3	5	38,898,038	70,365,108.1	2.24	2.63	20.54	34.23
45 to 64 Years	1,387	3,486	4,227	4,227	260.2	4	10	25,226,600	57,813,690.4	5.50	3.05	15.37	38.43
65+ Years	624	1,459	1,724	1,724	110.5	6	7	7,844,233	21,302,774.9	7.95	2.76	54.28	63.33

Table 3. Summary of Incident Ig Use and Hemolysis in the MSDD between January 1, 2006 and December 31, 2012, by Ig Product, Episode Extension Period, and Sex

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Flebogamma													
3 day episode extension													
Female	955	3,192	3,900	3,900	37.1	6	7	34,818,342	78,142,724.1	2.74	4.08	161.82	188.79
Male	917	2,988	3,840	3,840	35.3	3	4	32,841,498	71,306,520.7	2.79	4.19	84.92	113.23
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
14 day episode extension													
Female	955	3,192	3,900	3,900	131.6	8	9	34,818,342	78,142,724.1	2.74	4.08	60.79	68.38
Male	917	2,988	3,840	3,840	123.7	6	7	32,841,498	71,306,520.7	2.79	4.19	48.50	56.58
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
21 day episode extension													
Female	955	3,192	3,900	3,900	190.3	10	11	34,818,342	78,142,724.1	2.74	4.08	52.54	57.79
Male	917	2,988	3,840	3,840	178.9	6	7	32,841,498	71,306,520.7	2.79	4.19	33.54	39.13
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
28 day episode extension													
Female	955	3,192	3,900	3,900	243.3	11	13	34,818,342	78,142,724.1	2.74	4.08	45.22	53.44
Male	917	2,988	3,840	3,840	229.5	9	10	32,841,498	71,306,520.7	2.79	4.19	39.22	43.58
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
Gammagard Liquid													
3 day episode extension													
Female	4,772	18,880	21,663	21,663	216.4	12	14	34,818,790	78,142,779.5	13.71	4.54	55.45	64.69
Male	3,521	13,284	15,540	15,540	152.9	12	17	32,841,796	71,306,616.1	10.72	4.41	78.48	111.18
Unknown	1	12	12	12	0.1	0	0	18,209	30,914.8	5.49	12.00	0.00	0.00
14 day episode extension													
Female	4,772	18,880	21,663	21,663	774.1	17	22	34,818,790	78,142,779.5	13.71	4.54	21.96	28.42
Male	3,521	13,284	15,540	15,540	544.7	18	28	32,841,796	71,306,616.1	10.72	4.41	33.04	51.40
Unknown	1	12	12	12	0.5	0	0	18,209	30,914.8	5.49	12.00	0.00	0.00
21 day episode extension													
Female	4,772	18,880	21,663	21,663	1,118.8	20	34	34,818,790	78,142,779.5	13.71	4.54	17.88	30.39
Male	3,521	13,284	15,540	15,540	787.0	23	44	32,841,796	71,306,616.1	10.72	4.41	29.22	55.91
Unknown	1	12	12	12	0.7	0	0	18,209	30,914.8	5.49	12.00	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
Female	4,772	18,880	21,663	21,663	1,423.8	23	42	34,818,790	78,142,779.5	13.71	4.54	16.15	29.50
Male	3,521	13,284	15,540	15,540	1,004.0	28	56	32,841,796	71,306,616.1	10.72	4.41	27.89	55.77
Unknown	1	12	12	12	1.0	0	0	18,209	30,914.8	5.49	12.00	0.00	0.00
Gammaplex													
3 day episode extension													
Female	35	80	104	104	0.9	0	0	34,818,255	78,142,634.4	0.10	2.97	0.00	0.00
Male	15	40	52	52	0.5	0	0	32,841,439	71,306,373.9	0.05	3.47	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
14 day episode extension													
Female	35	80	104	104	3.3	0	0	34,818,255	78,142,634.4	0.10	2.97	0.00	0.00
Male	15	40	52	52	1.7	0	0	32,841,439	71,306,373.9	0.05	3.47	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
21 day episode extension													
Female	35	80	104	104	4.8	0	0	34,818,255	78,142,634.4	0.10	2.97	0.00	0.00
Male	15	40	52	52	2.4	0	0	32,841,439	71,306,373.9	0.05	3.47	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
28 day episode extension													
Female	35	80	104	104	6.1	0	0	34,818,255	78,142,634.4	0.10	2.97	0.00	0.00
Male	15	40	52	52	3.1	0	0	32,841,439	71,306,373.9	0.05	3.47	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
Gamunex													
3 day episode extension													
Female	3,015	12,525	14,794	14,794	144.6	4	4	34,818,589	78,142,224.4	8.66	4.91	27.66	27.66
Male	2,550	9,331	11,244	11,244	108.3	3	3	32,841,684	71,306,351.4	7.76	4.41	27.71	27.71
Unknown	3	34	35	35	0.4	0	0	18,210	30,912.4	16.47	11.67	0.00	0.00
14 day episode extension													
Female	3,015	12,525	14,794	14,794	514.4	7	7	34,818,589	78,142,224.4	8.66	4.91	13.61	13.61
Male	2,550	9,331	11,244	11,244	384.0	8	13	32,841,684	71,306,351.4	7.76	4.41	20.83	33.86
Unknown	3	34	35	35	1.4	0	0	18,210	30,912.4	16.47	11.67	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
21 day episode extension													
Female	3,015	12,525	14,794	14,794	741.9	11	12	34,818,589	78,142,224.4	8.66	4.91	14.83	16.18
Male	2,550	9,331	11,244	11,244	553.6	14	24	32,841,684	71,306,351.4	7.76	4.41	25.29	43.35
Unknown	3	34	35	35	2.1	0	0	18,210	30,912.4	16.47	11.67	0.00	0.00
28 day episode extension													
Female	3,015	12,525	14,794	14,794	943.6	13	15	34,818,589	78,142,224.4	8.66	4.91	13.78	15.90
Male	2,550	9,331	11,244	11,244	703.4	16	35	32,841,684	71,306,351.4	7.76	4.41	22.75	49.76
Unknown	3	34	35	35	2.7	0	0	18,210	30,912.4	16.47	11.67	0.00	0.00
Octagam													
3 day episode extension													
Female	1,197	4,268	4,953	4,953	49.2	5	11	34,818,445	78,142,795.0	3.44	4.14	101.58	223.48
Male	853	2,714	3,138	3,138	31.2	4	6	32,841,548	71,306,550.8	2.60	3.68	128.18	192.27
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
14 day episode extension													
Female	1,197	4,268	4,953	4,953	175.6	5	22	34,818,445	78,142,795.0	3.44	4.14	28.48	125.29
Male	853	2,714	3,138	3,138	111.5	8	10	32,841,548	71,306,550.8	2.60	3.68	71.75	89.69
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
21 day episode extension													
Female	1,197	4,268	4,953	4,953	254.1	7	30	34,818,445	78,142,795.0	3.44	4.14	27.55	118.08
Male	853	2,714	3,138	3,138	161.4	8	11	32,841,548	71,306,550.8	2.60	3.68	49.56	68.14
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
28 day episode extension													
Female	1,197	4,268	4,953	4,953	324.5	7	35	34,818,445	78,142,795.0	3.44	4.14	21.57	107.85
Male	853	2,714	3,138	3,138	206.8	8	11	32,841,548	71,306,550.8	2.60	3.68	38.68	53.18
Unknown	0	0	0	0	0.0	0	0	18,209	30,915.8	0.00	---	---	---
Privigen													
3 day episode extension													
Female	1,634	5,316	6,278	6,278	61.3	3	7	34,818,400	78,142,561.2	4.69	3.84	48.95	114.21
Male	1,286	4,176	5,253	5,253	49.1	7	7	32,841,561	71,306,271.8	3.92	4.08	142.63	142.63
Unknown	1	2	2	2	0.0	0	0	18,209	30,915.4	5.49	2.00	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
14 day episode extension													
Female	1,634	5,316	6,278	6,278	218.7	5	10	34,818,400	78,142,561.2	4.69	3.84	22.86	45.73
Male	1,286	4,176	5,253	5,253	172.2	9	13	32,841,561	71,306,271.8	3.92	4.08	52.27	75.50
Unknown	1	2	2	2	0.1	0	0	18,209	30,915.4	5.49	2.00	0.00	0.00
21 day episode extension													
Female	1,634	5,316	6,278	6,278	316.1	5	12	34,818,400	78,142,561.2	4.69	3.84	15.82	37.96
Male	1,286	4,176	5,253	5,253	248.4	9	16	32,841,561	71,306,271.8	3.92	4.08	36.24	64.42
Unknown	1	2	2	2	0.1	0	0	18,209	30,915.4	5.49	2.00	0.00	0.00
28 day episode extension													
Female	1,634	5,316	6,278	6,278	402.3	5	14	34,818,400	78,142,561.2	4.69	3.84	12.43	34.80
Male	1,286	4,176	5,253	5,253	317.2	12	21	32,841,561	71,306,271.8	3.92	4.08	37.83	66.20
Unknown	1	2	2	2	0.2	0	0	18,209	30,915.4	5.49	2.00	0.00	0.00
Lyophilized product IV													
3 day episode extension													
Female	2,884	10,893	12,919	12,919	125.7	8	9	34,818,598	78,142,901.7	8.28	4.48	63.62	71.58
Male	2,279	8,292	10,096	10,096	96.5	15	16	32,841,696	71,306,828.4	6.94	4.43	155.49	165.85
Unknown	2	43	43	43	0.5	0	0	18,209	30,912.6	10.98	21.50	0.00	0.00
14 day episode extension													
Female	2,884	10,893	12,919	12,919	448.4	11	13	34,818,598	78,142,901.7	8.28	4.48	24.53	28.99
Male	2,279	8,292	10,096	10,096	341.4	20	22	32,841,696	71,306,828.4	6.94	4.43	58.59	64.45
Unknown	2	43	43	43	1.8	0	0	18,209	30,912.6	10.98	21.50	0.00	0.00
21 day episode extension													
Female	2,884	10,893	12,919	12,919	648.1	13	15	34,818,598	78,142,901.7	8.28	4.48	20.06	23.14
Male	2,279	8,292	10,096	10,096	493.1	20	26	32,841,696	71,306,828.4	6.94	4.43	40.56	52.72
Unknown	2	43	43	43	2.6	0	0	18,209	30,912.6	10.98	21.50	0.00	0.00
28 day episode extension													
Female	2,884	10,893	12,919	12,919	825.8	16	19	34,818,598	78,142,901.7	8.28	4.48	19.38	23.01
Male	2,279	8,292	10,096	10,096	630.5	21	29	32,841,696	71,306,828.4	6.94	4.43	33.31	46.00
Unknown	2	43	43	43	3.4	0	0	18,209	30,912.6	10.98	21.50	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Non-lyophilized intramuscular route													
3 day episode extension													
Female	3,470	5,478	5,518	5,518	60.2	1	1	34,818,750	78,151,824.4	9.97	1.59	16.61	16.61
Male	2,373	3,171	3,206	3,206	34.9	0	0	32,841,745	71,313,342.0	7.23	1.35	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,210	30,916.2	0.00	---	---	---
14 day episode extension													
Female	3,470	5,478	5,518	5,518	222.1	1	1	34,818,750	78,151,824.4	9.97	1.59	4.50	4.50
Male	2,373	3,171	3,206	3,206	129.4	0	0	32,841,745	71,313,342.0	7.23	1.35	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,210	30,916.2	0.00	---	---	---
21 day episode extension													
Female	3,470	5,478	5,518	5,518	322.1	1	1	34,818,750	78,151,824.4	9.97	1.59	3.10	3.10
Male	2,373	3,171	3,206	3,206	188.5	0	0	32,841,745	71,313,342.0	7.23	1.35	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,210	30,916.2	0.00	---	---	---
28 day episode extension													
Female	3,470	5,478	5,518	5,518	417.5	1	1	34,818,750	78,151,824.4	9.97	1.59	2.40	2.40
Male	2,373	3,171	3,206	3,206	245.4	0	0	32,841,745	71,313,342.0	7.23	1.35	0.00	0.00
Unknown	0	0	0	0	0.0	0	0	18,210	30,916.2	0.00	---	---	---
Non-lyophilized unspecified route													
3 day episode extension													
Female	4,536	5,947	6,040	6,040	64.9	78	95	34,818,945	78,149,757.7	13.03	1.33	1202.75	1464.89
Male	3,370	4,267	4,342	4,342	46.5	60	68	32,841,970	71,311,671.2	10.26	1.29	1290.10	1462.12
Unknown	1	1	1	1	0.0	0	0	18,209	30,920.0	5.49	1.00	0.00	0.00
14 day episode extension													
Female	4,536	5,947	6,040	6,040	239.9	84	147	34,818,945	78,149,757.7	13.03	1.33	350.10	612.67
Male	3,370	4,267	4,342	4,342	171.8	68	105	32,841,970	71,311,671.2	10.26	1.29	395.85	611.23
Unknown	1	1	1	1	0.0	0	0	18,209	30,920.0	5.49	1.00	0.00	0.00
21 day episode extension													
Female	4,536	5,947	6,040	6,040	348.8	88	177	34,818,945	78,149,757.7	13.03	1.33	252.32	507.50
Male	3,370	4,267	4,342	4,342	249.2	74	128	32,841,970	71,311,671.2	10.26	1.29	296.92	513.59
Unknown	1	1	1	1	0.1	0	0	18,209	30,920.0	5.49	1.00	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
Female	4,536	5,947	6,040	6,040	454.8	89	199	34,818,945	78,149,757.7	13.03	1.33	195.70	437.58
Male	3,370	4,267	4,342	4,342	324.7	79	152	32,841,970	71,311,671.2	10.26	1.29	243.27	468.06
Unknown	1	1	1	1	0.1	0	0	18,209	30,920.0	5.49	1.00	0.00	0.00
Other IVIg, brand not specified													
3 day episode extension													
Female	1,626	3,886	4,607	4,607	45.0	3	5	34,818,509	78,143,636.9	4.67	2.83	66.72	111.20
Male	1,222	3,015	3,619	3,619	35.0	1	1	32,841,623	71,307,023.3	3.72	2.96	28.55	28.55
Unknown	1	14	14	14	0.2	0	0	18,209	30,913.3	5.49	14.00	0.00	0.00
14 day episode extension													
Female	1,626	3,886	4,607	4,607	158.4	7	13	34,818,509	78,143,636.9	4.67	2.83	44.20	82.08
Male	1,222	3,015	3,619	3,619	123.4	2	2	32,841,623	71,307,023.3	3.72	2.96	16.21	16.21
Unknown	1	14	14	14	0.6	0	0	18,209	30,913.3	5.49	14.00	0.00	0.00
21 day episode extension													
Female	1,626	3,886	4,607	4,607	227.8	7	15	34,818,509	78,143,636.9	4.67	2.83	30.72	65.84
Male	1,222	3,015	3,619	3,619	177.4	3	4	32,841,623	71,307,023.3	3.72	2.96	16.91	22.55
Unknown	1	14	14	14	0.8	0	0	18,209	30,913.3	5.49	14.00	0.00	0.00
28 day episode extension													
Female	1,626	3,886	4,607	4,607	289.7	9	17	34,818,509	78,143,636.9	4.67	2.83	31.06	58.67
Male	1,222	3,015	3,619	3,619	225.9	4	5	32,841,623	71,307,023.3	3.72	2.96	17.70	22.13
Unknown	1	14	14	14	1.1	0	0	18,209	30,913.3	5.49	14.00	0.00	0.00

Table 4: Summary of Incident Ig Use and Hemolysis in the MSDD between January 1, 2006 and December 31, 2012, by Ig Product, Episode Extension Period, and Year

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Flebogamma													
<i>3 day episode extension</i>													
2006	0	0	0	0	0.0	0	0	14,802,241	8,849,162.5	0.00	---	---	---
2007	124	196	229	229	2.2	0	0	18,026,646	12,829,338.6	0.69	1.85	0.00	0.00
2008	370	818	957	957	9.4	3	4	34,328,208	21,391,680.0	1.08	2.59	320.49	427.32
2009	538	1,204	1,548	1,548	14.3	0	0	35,803,995	27,488,173.9	1.50	2.88	0.00	0.00
2010	572	1,273	1,625	1,625	15.0	0	0	34,621,390	26,681,529.0	1.65	2.84	0.00	0.00
2011	625	1,468	1,847	1,847	17.2	4	5	34,001,971	26,481,098.8	1.84	2.96	232.42	290.53
2012	543	1,221	1,534	1,534	14.3	2	2	33,404,936	25,759,177.8	1.63	2.83	139.97	139.97
<i>14 day episode extension</i>													
2006	0	0	0	0	0.0	0	0	14,802,241	8,849,162.5	0.00	---	---	---
2007	124	196	229	229	8.1	0	0	18,026,646	12,829,338.6	0.69	1.85	0.00	0.00
2008	370	818	957	957	33.6	3	4	34,328,208	21,391,680.0	1.08	2.59	89.20	118.94
2009	538	1,204	1,548	1,548	49.9	3	3	35,803,995	27,488,173.9	1.50	2.88	60.16	60.16
2010	572	1,273	1,625	1,625	52.8	1	1	34,621,390	26,681,529.0	1.65	2.84	18.94	18.94
2011	625	1,468	1,847	1,847	60.6	5	6	34,001,971	26,481,098.8	1.84	2.96	82.49	98.99
2012	543	1,221	1,534	1,534	50.3	2	2	33,404,936	25,759,177.8	1.63	2.83	39.74	39.74
<i>21 day episode extension</i>													
2006	0	0	0	0	0.0	0	0	14,802,241	8,849,162.5	0.00	---	---	---
2007	124	196	229	229	11.7	0	0	18,026,646	12,829,338.6	0.69	1.85	0.00	0.00
2008	370	818	957	957	48.9	3	4	34,328,208	21,391,680.0	1.08	2.59	61.38	81.84
2009	538	1,204	1,548	1,548	72.0	3	3	35,803,995	27,488,173.9	1.50	2.88	41.68	41.68
2010	572	1,273	1,625	1,625	76.4	2	2	34,621,390	26,681,529.0	1.65	2.84	26.17	26.17
2011	625	1,468	1,847	1,847	87.6	6	7	34,001,971	26,481,098.8	1.84	2.96	68.50	79.91
2012	543	1,221	1,534	1,534	72.7	2	2	33,404,936	25,759,177.8	1.63	2.83	27.53	27.53

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,241	8,849,162.5	0.00	---	---	---
2007	124	196	229	229	15.0	0	0	18,026,646	12,829,338.6	0.69	1.85	0.00	0.00
2008	370	818	957	957	62.9	5	6	34,328,208	21,391,680.0	1.08	2.59	79.54	95.45
2009	538	1,204	1,548	1,548	92.2	4	4	35,803,995	27,488,173.9	1.50	2.88	43.38	43.38
2010	572	1,273	1,625	1,625	97.7	3	4	34,621,390	26,681,529.0	1.65	2.84	30.71	40.95
2011	625	1,468	1,847	1,847	112.1	6	7	34,001,971	26,481,098.8	1.84	2.96	53.54	62.47
2012	543	1,221	1,534	1,534	93.0	2	2	33,404,936	25,759,177.8	1.63	2.83	21.51	21.51
Gammagard Liquid													
3 day episode extension													
2006	6	16	38	38	0.2	0	0	14,802,217	8,849,145.9	0.04	6.33	0.00	0.00
2007	334	586	712	712	6.8	0	0	18,026,654	12,829,248.6	1.85	2.13	0.00	0.00
2008	1,918	4,211	4,963	4,963	48.9	2	3	34,328,536	21,391,451.0	5.59	2.59	40.92	61.39
2009	2,443	5,901	6,978	6,978	68.4	7	7	35,804,545	27,488,058.4	6.82	2.86	102.30	102.30
2010	2,551	6,354	7,272	7,272	72.6	6	9	34,622,107	26,681,536.7	7.37	2.85	82.61	123.92
2011	2,962	7,594	8,670	8,670	86.7	5	6	34,002,864	26,481,224.4	8.71	2.93	57.66	69.19
2012	2,890	7,514	8,582	8,582	85.8	4	6	33,406,205	25,759,645.5	8.65	2.97	46.64	69.96
14 day episode extension													
2006	6	16	38	38	0.7	0	0	14,802,217	8,849,145.9	0.04	6.33	0.00	0.00
2007	334	586	712	712	24.1	0	0	18,026,654	12,829,248.6	1.85	2.13	0.00	0.00
2008	1,918	4,211	4,963	4,963	172.9	3	6	34,328,536	21,391,451.0	5.59	2.59	17.35	34.71
2009	2,443	5,901	6,978	6,978	242.3	10	11	35,804,545	27,488,058.4	6.82	2.86	41.27	45.40
2010	2,551	6,354	7,272	7,272	260.6	9	15	34,622,107	26,681,536.7	7.37	2.85	34.54	57.57
2011	2,962	7,594	8,670	8,670	311.0	8	11	34,002,864	26,481,224.4	8.71	2.93	25.72	35.37
2012	2,890	7,514	8,582	8,582	307.8	5	7	33,406,205	25,759,645.5	8.65	2.97	16.25	22.75
21 day episode extension													
2006	6	16	38	38	1.0	0	0	14,802,217	8,849,145.9	0.04	6.33	0.00	0.00
2007	334	586	712	712	34.6	0	0	18,026,654	12,829,248.6	1.85	2.13	0.00	0.00
2008	1,918	4,211	4,963	4,963	249.7	3	10	34,328,536	21,391,451.0	5.59	2.59	12.01	40.05
2009	2,443	5,901	6,978	6,978	349.6	12	21	35,804,545	27,488,058.4	6.82	2.86	34.32	60.06
2010	2,551	6,354	7,272	7,272	376.7	10	17	34,622,107	26,681,536.7	7.37	2.85	26.55	45.13
2011	2,962	7,594	8,670	8,670	450.0	11	18	34,002,864	26,481,224.4	8.71	2.93	24.44	40.00
2012	2,890	7,514	8,582	8,582	444.9	7	12	33,406,205	25,759,645.5	8.65	2.97	15.73	26.97

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	6	16	38	38	1.3	0	0	14,802,217	8,849,145.9	0.04	6.33	0.00	0.00
2007	334	586	712	712	44.3	0	0	18,026,654	12,829,248.6	1.85	2.13	0.00	0.00
2008	1,918	4,211	4,963	4,963	317.9	3	10	34,328,536	21,391,451.0	5.59	2.59	9.44	31.46
2009	2,443	5,901	6,978	6,978	445.0	16	30	35,804,545	27,488,058.4	6.82	2.86	35.96	67.42
2010	2,551	6,354	7,272	7,272	479.9	12	19	34,622,107	26,681,536.7	7.37	2.85	25.00	39.59
2011	2,962	7,594	8,670	8,670	574.0	13	25	34,002,864	26,481,224.4	8.71	2.93	22.65	43.55
2012	2,890	7,514	8,582	8,582	566.5	7	14	33,406,205	25,759,645.5	8.65	2.97	12.36	24.71
Gammplex													
3 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,233	8,849,169.9	0.00	---	---	---
2007	0	0	0	0	0.0	0	0	18,026,619	12,829,371.8	0.00	---	---	---
2008	0	0	0	0	0.0	0	0	34,328,139	21,391,735.8	0.00	---	---	---
2009	0	0	0	0	0.0	0	0	35,803,859	27,488,182.8	0.00	---	---	---
2010	0	0	0	0	0.0	0	0	34,621,168	26,681,475.0	0.00	---	---	---
2011	4	4	4	4	0.0	0	0	34,001,690	26,481,011.2	0.01	1.00	0.00	0.00
2012	46	116	152	152	1.4	0	0	33,404,606	25,758,977.7	0.14	3.30	0.00	0.00
14 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,233	8,849,169.9	0.00	---	---	---
2007	0	0	0	0	0.0	0	0	18,026,619	12,829,371.8	0.00	---	---	---
2008	0	0	0	0	0.0	0	0	34,328,139	21,391,735.8	0.00	---	---	---
2009	0	0	0	0	0.0	0	0	35,803,859	27,488,182.8	0.00	---	---	---
2010	0	0	0	0	0.0	0	0	34,621,168	26,681,475.0	0.00	---	---	---
2011	4	4	4	4	0.2	0	0	34,001,690	26,481,011.2	0.01	1.00	0.00	0.00
2012	46	116	152	152	4.9	0	0	33,404,606	25,758,977.7	0.14	3.30	0.00	0.00
21 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,233	8,849,169.9	0.00	---	---	---
2007	0	0	0	0	0.0	0	0	18,026,619	12,829,371.8	0.00	---	---	---
2008	0	0	0	0	0.0	0	0	34,328,139	21,391,735.8	0.00	---	---	---
2009	0	0	0	0	0.0	0	0	35,803,859	27,488,182.8	0.00	---	---	---
2010	0	0	0	0	0.0	0	0	34,621,168	26,681,475.0	0.00	---	---	---
2011	4	4	4	4	0.2	0	0	34,001,690	26,481,011.2	0.01	1.00	0.00	0.00
2012	46	116	152	152	7.0	0	0	33,404,606	25,758,977.7	0.14	3.30	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,233	8,849,169.9	0.00	---	---	---
2007	0	0	0	0	0.0	0	0	18,026,619	12,829,371.8	0.00	---	---	---
2008	0	0	0	0	0.0	0	0	34,328,139	21,391,735.8	0.00	---	---	---
2009	0	0	0	0	0.0	0	0	35,803,859	27,488,182.8	0.00	---	---	---
2010	0	0	0	0	0.0	0	0	34,621,168	26,681,475.0	0.00	---	---	---
2011	4	4	4	4	0.3	0	0	34,001,690	26,481,011.2	0.01	1.00	0.00	0.00
2012	46	116	152	152	8.9	0	0	33,404,606	25,758,977.7	0.14	3.30	0.00	0.00
Gamunex													
3 day episode extension													
2006	1	1	1	1	0.0	0	0	14,802,209	8,849,144.8	0.01	1.00	0.00	0.00
2007	351	608	761	761	7.2	0	0	18,026,642	12,829,245.0	1.95	2.17	0.00	0.00
2008	1,319	3,102	3,644	3,644	35.7	3	3	34,328,365	21,391,449.5	3.84	2.76	83.97	83.97
2009	1,689	4,306	5,139	5,139	49.8	1	1	35,804,245	27,487,933.9	4.72	3.04	20.06	20.06
2010	1,790	4,426	5,282	5,282	51.2	0	0	34,621,708	26,681,394.8	5.17	2.95	0.00	0.00
2011	1,800	4,648	5,502	5,502	53.6	2	2	34,002,411	26,481,056.9	5.29	3.06	37.31	37.31
2012	1,891	4,799	5,744	5,744	55.6	1	1	33,405,472	25,759,263.2	5.66	3.04	17.99	17.99
14 day episode extension													
2006	1	1	1	1	0.0	0	0	14,802,209	8,849,144.8	0.01	1.00	0.00	0.00
2007	351	608	761	761	25.3	0	0	18,026,642	12,829,245.0	1.95	2.17	0.00	0.00
2008	1,319	3,102	3,644	3,644	127.5	5	6	34,328,365	21,391,449.5	3.84	2.76	39.23	47.07
2009	1,689	4,306	5,139	5,139	177.2	1	1	35,804,245	27,487,933.9	4.72	3.04	5.64	5.64
2010	1,790	4,426	5,282	5,282	182.0	3	3	34,621,708	26,681,394.8	5.17	2.95	16.48	16.48
2011	1,800	4,648	5,502	5,502	190.6	5	8	34,002,411	26,481,056.9	5.29	3.06	26.23	41.97
2012	1,891	4,799	5,744	5,744	197.1	1	2	33,405,472	25,759,263.2	5.66	3.04	5.07	10.14
21 day episode extension													
2006	1	1	1	1	0.1	0	0	14,802,209	8,849,144.8	0.01	1.00	0.00	0.00
2007	351	608	761	761	36.5	0	0	18,026,642	12,829,245.0	1.95	2.17	0.00	0.00
2008	1,319	3,102	3,644	3,644	184.1	7	10	34,328,365	21,391,449.5	3.84	2.76	38.03	54.33
2009	1,689	4,306	5,139	5,139	255.7	2	2	35,804,245	27,487,933.9	4.72	3.04	7.82	7.82
2010	1,790	4,426	5,282	5,282	262.7	3	3	34,621,708	26,681,394.8	5.17	2.95	11.42	11.42
2011	1,800	4,648	5,502	5,502	274.5	9	15	34,002,411	26,481,056.9	5.29	3.06	32.79	54.65
2012	1,891	4,799	5,744	5,744	284.1	4	6	33,405,472	25,759,263.2	5.66	3.04	14.08	21.12

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	1	1	1	1	0.1	0	0	14,802,209	8,849,144.8	0.01	1.00	0.00	0.00
2007	351	608	761	761	46.6	0	0	18,026,642	12,829,245.0	1.95	2.17	0.00	0.00
2008	1,319	3,102	3,644	3,644	234.0	7	12	34,328,365	21,391,449.5	3.84	2.76	29.91	51.28
2009	1,689	4,306	5,139	5,139	324.8	2	2	35,804,245	27,487,933.9	4.72	3.04	6.16	6.16
2010	1,790	4,426	5,282	5,282	334.4	5	5	34,621,708	26,681,394.8	5.17	2.95	14.95	14.95
2011	1,800	4,648	5,502	5,502	349.0	10	23	34,002,411	26,481,056.9	5.29	3.06	28.66	65.91
2012	1,891	4,799	5,744	5,744	360.8	5	8	33,405,472	25,759,263.2	5.66	3.04	13.86	22.17
Octagam													
3 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,248	8,849,181.8	0.00	---	---	---
2007	157	276	306	306	3.1	2	4	18,026,656	12,829,361.9	0.87	1.95	646.46	1292.92
2008	700	1,638	1,886	1,886	18.7	1	2	34,328,386	21,391,691.7	2.04	2.69	53.34	106.67
2009	814	2,332	2,739	2,739	27.2	3	8	35,804,211	27,488,212.5	2.27	3.36	110.27	294.05
2010	602	1,369	1,499	1,499	15.4	1	1	34,621,561	26,681,618.2	1.74	2.49	64.86	64.86
2011	66	130	142	142	1.5	0	0	34,001,932	26,481,180.6	0.19	2.15	0.00	0.00
2012	588	1,237	1,519	1,519	14.5	2	2	33,404,788	25,759,014.7	1.76	2.58	138.01	138.01
14 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,248	8,849,181.8	0.00	---	---	---
2007	157	276	306	306	11.2	2	4	18,026,656	12,829,361.9	0.87	1.95	178.00	355.99
2008	700	1,638	1,886	1,886	67.2	2	8	34,328,386	21,391,691.7	2.04	2.69	29.75	119.00
2009	814	2,332	2,739	2,739	96.1	5	10	35,804,211	27,488,212.5	2.27	3.36	52.03	104.07
2010	602	1,369	1,499	1,499	56.1	1	7	34,621,561	26,681,618.2	1.74	2.49	17.83	124.84
2011	66	130	142	142	5.3	0	0	34,001,932	26,481,180.6	0.19	2.15	0.00	0.00
2012	588	1,237	1,519	1,519	51.1	3	3	33,404,788	25,759,014.7	1.76	2.58	58.67	58.67
21 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,248	8,849,181.8	0.00	---	---	---
2007	157	276	306	306	16.4	3	5	18,026,656	12,829,361.9	0.87	1.95	183.33	305.55
2008	700	1,638	1,886	1,886	97.1	3	14	34,328,386	21,391,691.7	2.04	2.69	30.88	144.13
2009	814	2,332	2,739	2,739	139.0	5	11	35,804,211	27,488,212.5	2.27	3.36	35.97	79.13
2010	602	1,369	1,499	1,499	81.4	1	8	34,621,561	26,681,618.2	1.74	2.49	12.28	98.23
2011	66	130	142	142	7.7	0	0	34,001,932	26,481,180.6	0.19	2.15	0.00	0.00
2012	588	1,237	1,519	1,519	73.8	3	3	33,404,788	25,759,014.7	1.76	2.58	40.65	40.65

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,248	8,849,181.8	0.00	---	---	---
2007	157	276	306	306	21.0	3	5	18,026,656	12,829,361.9	0.87	1.95	142.94	238.23
2008	700	1,638	1,886	1,886	124.1	3	18	34,328,386	21,391,691.7	2.04	2.69	24.18	145.07
2009	814	2,332	2,739	2,739	177.8	5	12	35,804,211	27,488,212.5	2.27	3.36	28.12	67.48
2010	602	1,369	1,499	1,499	104.4	1	8	34,621,561	26,681,618.2	1.74	2.49	9.58	76.63
2011	66	130	142	142	9.9	0	0	34,001,932	26,481,180.6	0.19	2.15	0.00	0.00
2012	588	1,237	1,519	1,519	94.1	3	3	33,404,788	25,759,014.7	1.76	2.58	31.87	31.87
Privigen													
3 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,230	8,849,159.2	0.00	---	---	---
2007	1	1	1	1	0.0	0	0	18,026,607	12,829,349.9	0.01	1.00	0.00	0.00
2008	231	433	520	520	5.0	1	1	34,328,194	21,391,669.3	0.67	2.25	198.83	198.83
2009	484	1,085	1,324	1,324	12.6	0	0	35,803,946	27,488,095.6	1.35	2.74	0.00	0.00
2010	882	1,982	2,476	2,476	23.3	1	2	34,621,315	26,681,356.0	2.55	2.81	42.90	85.81
2011	1,174	2,753	3,347	3,347	32.0	4	4	34,001,987	26,480,968.6	3.45	2.85	124.94	124.94
2012	1,325	3,240	3,865	3,865	37.4	4	7	33,405,076	25,759,149.8	3.97	2.92	106.91	187.09
14 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,230	8,849,159.2	0.00	---	---	---
2007	1	1	1	1	0.0	0	0	18,026,607	12,829,349.9	0.01	1.00	0.00	0.00
2008	231	433	520	520	17.7	1	1	34,328,194	21,391,669.3	0.67	2.25	56.59	56.59
2009	484	1,085	1,324	1,324	44.6	0	0	35,803,946	27,488,095.6	1.35	2.74	0.00	0.00
2010	882	1,982	2,476	2,476	81.6	2	3	34,621,315	26,681,356.0	2.55	2.81	24.50	36.75
2011	1,174	2,753	3,347	3,347	113.5	6	10	34,001,987	26,480,968.6	3.45	2.85	52.88	88.13
2012	1,325	3,240	3,865	3,865	133.6	5	9	33,405,076	25,759,149.8	3.97	2.92	37.43	67.38
21 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,230	8,849,159.2	0.00	---	---	---
2007	1	1	1	1	0.1	0	0	18,026,607	12,829,349.9	0.01	1.00	0.00	0.00
2008	231	433	520	520	25.5	1	1	34,328,194	21,391,669.3	0.67	2.25	39.18	39.18
2009	484	1,085	1,324	1,324	64.3	0	0	35,803,946	27,488,095.6	1.35	2.74	0.00	0.00
2010	882	1,982	2,476	2,476	117.5	2	3	34,621,315	26,681,356.0	2.55	2.81	17.03	25.54
2011	1,174	2,753	3,347	3,347	163.9	6	13	34,001,987	26,480,968.6	3.45	2.85	36.60	79.29
2012	1,325	3,240	3,865	3,865	193.3	5	11	33,405,076	25,759,149.8	3.97	2.92	25.87	56.91

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	0	0	0	0	0.0	0	0	14,802,230	8,849,159.2	0.00	---	---	---
2007	1	1	1	1	0.1	0	0	18,026,607	12,829,349.9	0.01	1.00	0.00	0.00
2008	231	433	520	520	32.6	1	1	34,328,194	21,391,669.3	0.67	2.25	30.66	30.66
2009	484	1,085	1,324	1,324	81.5	1	1	35,803,946	27,488,095.6	1.35	2.74	12.27	12.27
2010	882	1,982	2,476	2,476	149.1	2	3	34,621,315	26,681,356.0	2.55	2.81	13.41	20.12
2011	1,174	2,753	3,347	3,347	209.2	7	17	34,001,987	26,480,968.6	3.45	2.85	33.46	81.26
2012	1,325	3,240	3,865	3,865	247.1	6	13	33,405,076	25,759,149.8	3.97	2.92	24.28	52.61
Lyophilized product IV													
3 day episode extension													
2006	916	1,806	2,209	2,209	21.1	1	1	14,802,433	8,849,034.3	6.19	2.41	47.41	47.41
2007	1,228	2,987	3,538	3,538	34.4	4	5	18,026,960	12,829,241.5	6.81	2.88	116.27	145.33
2008	1,794	4,106	4,836	4,836	47.4	5	6	34,328,796	21,391,701.6	5.23	2.70	105.50	126.60
2009	1,613	4,050	4,862	4,862	46.8	5	5	35,804,618	27,488,331.7	4.51	3.01	106.80	106.80
2010	1,051	2,512	3,043	3,043	29.1	6	6	34,621,933	26,681,764.0	3.04	2.90	205.91	205.91
2011	869	2,234	2,729	2,729	26.1	1	1	34,002,348	26,481,283.6	2.56	3.14	38.33	38.33
2012	649	1,533	1,841	1,841	17.8	1	1	33,405,234	25,759,285.9	1.94	2.84	56.33	56.33
14 day episode extension													
2006	916	1,806	2,209	2,209	74.4	3	3	14,802,433	8,849,034.3	6.19	2.41	40.31	40.31
2007	1,228	2,987	3,538	3,538	122.7	6	7	18,026,960	12,829,241.5	6.81	2.88	48.90	57.06
2008	1,794	4,106	4,836	4,836	168.6	5	6	34,328,796	21,391,701.6	5.23	2.70	29.66	35.60
2009	1,613	4,050	4,862	4,862	166.8	5	5	35,804,618	27,488,331.7	4.51	3.01	29.98	29.98
2010	1,051	2,512	3,043	3,043	103.6	7	8	34,621,933	26,681,764.0	3.04	2.90	67.60	77.25
2011	869	2,234	2,729	2,729	92.3	2	3	34,002,348	26,481,283.6	2.56	3.14	21.68	32.51
2012	649	1,533	1,841	1,841	63.2	3	3	33,405,234	25,759,285.9	1.94	2.84	47.44	47.44
21 day episode extension													
2006	916	1,806	2,209	2,209	107.2	3	3	14,802,433	8,849,034.3	6.19	2.41	27.98	27.98
2007	1,228	2,987	3,538	3,538	177.3	6	7	18,026,960	12,829,241.5	6.81	2.88	33.85	39.49
2008	1,794	4,106	4,836	4,836	243.6	6	7	34,328,796	21,391,701.6	5.23	2.70	24.63	28.73
2009	1,613	4,050	4,862	4,862	241.4	5	6	35,804,618	27,488,331.7	4.51	3.01	20.71	24.86
2010	1,051	2,512	3,043	3,043	149.6	7	11	34,621,933	26,681,764.0	3.04	2.90	46.78	73.51
2011	869	2,234	2,729	2,729	133.3	2	3	34,002,348	26,481,283.6	2.56	3.14	15.01	22.51
2012	649	1,533	1,841	1,841	91.5	4	4	33,405,234	25,759,285.9	1.94	2.84	43.73	43.73

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	916	1,806	2,209	2,209	136.3	4	4	14,802,433	8,849,034.3	6.19	2.41	29.35	29.35
2007	1,228	2,987	3,538	3,538	226.2	6	7	18,026,960	12,829,241.5	6.81	2.88	26.53	30.95
2008	1,794	4,106	4,836	4,836	311.6	6	8	34,328,796	21,391,701.6	5.23	2.70	19.26	25.68
2009	1,613	4,050	4,862	4,862	308.3	6	7	35,804,618	27,488,331.7	4.51	3.01	19.46	22.71
2010	1,051	2,512	3,043	3,043	190.5	7	13	34,621,933	26,681,764.0	3.04	2.90	36.75	68.25
2011	869	2,234	2,729	2,729	170.0	3	4	34,002,348	26,481,283.6	2.56	3.14	17.65	23.53
2012	649	1,533	1,841	1,841	116.9	5	5	33,405,234	25,759,285.9	1.94	2.84	42.77	42.77
Non-lyophilized intramuscular route													
3 day episode extension													
2006	994	1,249	1,252	1,252	13.7	0	0	14,802,408	8,849,475.7	6.72	1.26	0.00	0.00
2007	1,263	1,502	1,508	1,508	16.5	0	0	18,027,702	12,830,742.2	7.01	1.19	0.00	0.00
2008	1,183	1,575	1,581	1,581	17.3	0	0	34,330,315	21,393,875.8	3.45	1.34	0.00	0.00
2009	1,023	1,481	1,517	1,517	16.4	0	0	35,806,673	27,490,963.5	2.86	1.48	0.00	0.00
2010	1,005	1,383	1,395	1,395	15.2	0	0	34,624,306	26,684,577.0	2.90	1.39	0.00	0.00
2011	597	800	803	803	8.8	0	0	34,005,111	26,484,294.6	1.76	1.35	0.00	0.00
2012	466	659	668	668	7.2	1	1	33,407,959	25,762,153.9	1.39	1.43	138.14	138.14
14 day episode extension													
2006	994	1,249	1,252	1,252	51.1	0	0	14,802,408	8,849,475.7	6.72	1.26	0.00	0.00
2007	1,263	1,502	1,508	1,508	61.5	0	0	18,027,702	12,830,742.2	7.01	1.19	0.00	0.00
2008	1,183	1,575	1,581	1,581	63.9	0	0	34,330,315	21,393,875.8	3.45	1.34	0.00	0.00
2009	1,023	1,481	1,517	1,517	60.2	0	0	35,806,673	27,490,963.5	2.86	1.48	0.00	0.00
2010	1,005	1,383	1,395	1,395	56.0	0	0	34,624,306	26,684,577.0	2.90	1.39	0.00	0.00
2011	597	800	803	803	32.3	0	0	34,005,111	26,484,294.6	1.76	1.35	0.00	0.00
2012	466	659	668	668	26.6	1	1	33,407,959	25,762,153.9	1.39	1.43	37.62	37.62
21 day episode extension													
2006	994	1,249	1,252	1,252	74.7	0	0	14,802,408	8,849,475.7	6.72	1.26	0.00	0.00
2007	1,263	1,502	1,508	1,508	89.8	0	0	18,027,702	12,830,742.2	7.01	1.19	0.00	0.00
2008	1,183	1,575	1,581	1,581	92.8	0	0	34,330,315	21,393,875.8	3.45	1.34	0.00	0.00
2009	1,023	1,481	1,517	1,517	86.9	0	0	35,806,673	27,490,963.5	2.86	1.48	0.00	0.00
2010	1,005	1,383	1,395	1,395	81.1	0	0	34,624,306	26,684,577.0	2.90	1.39	0.00	0.00
2011	597	800	803	803	46.8	0	0	34,005,111	26,484,294.6	1.76	1.35	0.00	0.00
2012	466	659	668	668	38.5	1	1	33,407,959	25,762,153.9	1.39	1.43	26.00	26.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	994	1,249	1,252	1,252	97.7	0	0	14,802,408	8,849,475.7	6.72	1.26	0.00	0.00
2007	1,263	1,502	1,508	1,508	117.4	0	0	18,027,702	12,830,742.2	7.01	1.19	0.00	0.00
2008	1,183	1,575	1,581	1,581	120.7	0	0	34,330,315	21,393,875.8	3.45	1.34	0.00	0.00
2009	1,023	1,481	1,517	1,517	112.2	0	0	35,806,673	27,490,963.5	2.86	1.48	0.00	0.00
2010	1,005	1,383	1,395	1,395	105.0	0	0	34,624,306	26,684,577.0	2.90	1.39	0.00	0.00
2011	597	800	803	803	60.3	0	0	34,005,111	26,484,294.6	1.76	1.35	0.00	0.00
2012	466	659	668	668	49.7	1	1	33,407,959	25,762,153.9	1.39	1.43	20.14	20.14
Non-lyophilized unspecified route													
3 day episode extension													
2006	376	535	545	545	5.9	7	7	14,802,343	8,849,234.2	2.54	1.45	1196.42	1196.42
2007	591	777	789	789	8.5	12	14	18,027,010	12,829,719.2	3.28	1.34	1415.24	1651.11
2008	1,325	1,623	1,636	1,636	17.6	28	35	34,329,190	21,392,672.0	3.86	1.23	1592.00	1990.00
2009	1,614	2,007	2,057	2,057	22.0	18	21	35,805,662	27,489,973.0	4.51	1.27	818.54	954.96
2010	1,596	1,843	1,871	1,871	20.1	21	28	34,623,711	26,683,983.0	4.61	1.17	1043.86	1391.81
2011	1,677	1,923	1,957	1,957	21.0	17	20	34,004,863	26,484,131.8	4.93	1.17	808.18	950.80
2012	1,428	1,507	1,528	1,528	16.3	35	38	33,408,386	25,762,635.7	4.27	1.07	2146.00	2329.95
14 day episode extension													
2006	376	535	545	545	21.6	7	9	14,802,343	8,849,234.2	2.54	1.45	324.79	417.59
2007	591	777	789	789	31.3	12	16	18,027,010	12,829,719.2	3.28	1.34	383.97	511.96
2008	1,325	1,623	1,636	1,636	65.2	28	54	34,329,190	21,392,672.0	3.86	1.23	429.67	828.65
2009	1,614	2,007	2,057	2,057	81.3	20	32	35,805,662	27,489,973.0	4.51	1.27	245.89	393.43
2010	1,596	1,843	1,871	1,871	74.2	23	49	34,623,711	26,683,983.0	4.61	1.17	309.77	659.95
2011	1,677	1,923	1,957	1,957	77.9	19	38	34,004,863	26,484,131.8	4.93	1.17	243.95	487.91
2012	1,428	1,507	1,528	1,528	60.3	43	54	33,408,386	25,762,635.7	4.27	1.07	712.89	895.26
21 day episode extension													
2006	376	535	545	545	31.4	7	9	14,802,343	8,849,234.2	2.54	1.45	222.81	286.47
2007	591	777	789	789	45.4	12	18	18,027,010	12,829,719.2	3.28	1.34	264.32	396.48
2008	1,325	1,623	1,636	1,636	94.2	28	60	34,329,190	21,392,672.0	3.86	1.23	297.36	637.19
2009	1,614	2,007	2,057	2,057	118.2	21	38	35,805,662	27,489,973.0	4.51	1.27	177.68	321.52
2010	1,596	1,843	1,871	1,871	107.9	25	63	34,623,711	26,683,983.0	4.61	1.17	231.70	583.88
2011	1,677	1,923	1,957	1,957	113.1	23	51	34,004,863	26,484,131.8	4.93	1.17	203.31	450.83
2012	1,428	1,507	1,528	1,528	87.9	46	66	33,408,386	25,762,635.7	4.27	1.07	523.54	751.17

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension													
2006	376	535	545	545	41.2	7	9	14,802,343	8,849,234.2	2.54	1.45	170.03	218.61
2007	591	777	789	789	59.4	12	21	18,027,010	12,829,719.2	3.28	1.34	201.99	353.48
2008	1,325	1,623	1,636	1,636	121.8	29	65	34,329,190	21,392,672.0	3.86	1.23	238.00	533.45
2009	1,614	2,007	2,057	2,057	154.0	22	43	35,805,662	27,489,973.0	4.51	1.27	142.83	279.17
2010	1,596	1,843	1,871	1,871	140.6	26	73	34,623,711	26,683,983.0	4.61	1.17	184.98	519.38
2011	1,677	1,923	1,957	1,957	147.5	26	63	34,004,863	26,484,131.8	4.93	1.17	176.29	427.16
2012	1,428	1,507	1,528	1,528	115.1	46	77	33,408,386	25,762,635.7	4.27	1.07	399.62	668.92
Other IVIg, brand not specified													
3 day episode extension													
2006	1,383	2,742	3,295	3,295	31.9	2	3	14,802,561	8,849,042.9	9.34	2.38	62.73	94.10
2007	1,547	3,246	3,830	3,830	37.5	2	3	18,027,239	12,829,437.3	8.58	2.48	53.38	80.07
2008	156	219	225	225	2.4	0	0	34,328,645	21,392,117.6	0.45	1.44	0.00	0.00
2009	152	219	262	262	2.6	0	0	35,804,287	27,488,569.6	0.42	1.72	0.00	0.00
2010	86	129	158	158	1.5	0	0	34,621,586	26,681,827.5	0.25	1.84	0.00	0.00
2011	168	247	333	333	3.0	0	0	34,002,045	26,481,315.6	0.49	1.98	0.00	0.00
2012	83	113	137	137	1.3	0	0	33,404,942	25,759,262.9	0.25	1.65	0.00	0.00
14 day episode extension													
2006	1,383	2,742	3,295	3,295	111.8	4	6	14,802,561	8,849,042.9	9.34	2.38	35.77	53.65
2007	1,547	3,246	3,830	3,830	132.8	5	9	18,027,239	12,829,437.3	8.58	2.48	37.66	67.79
2008	156	219	225	225	9.0	0	0	34,328,645	21,392,117.6	0.45	1.44	0.00	0.00
2009	152	219	262	262	9.0	0	0	35,804,287	27,488,569.6	0.42	1.72	0.00	0.00
2010	86	129	158	158	5.3	0	0	34,621,586	26,681,827.5	0.25	1.84	0.00	0.00
2011	168	247	333	333	10.0	0	0	34,002,045	26,481,315.6	0.49	1.98	0.00	0.00
2012	83	113	137	137	4.5	0	0	33,404,942	25,759,262.9	0.25	1.65	0.00	0.00
21 day episode extension													
2006	1,383	2,742	3,295	3,295	160.6	5	10	14,802,561	8,849,042.9	9.34	2.38	31.14	62.28
2007	1,547	3,246	3,830	3,830	191.6	5	9	18,027,239	12,829,437.3	8.58	2.48	26.10	46.98
2008	156	219	225	225	13.0	0	0	34,328,645	21,392,117.6	0.45	1.44	0.00	0.00
2009	152	219	262	262	12.9	0	0	35,804,287	27,488,569.6	0.42	1.72	0.00	0.00
2010	86	129	158	158	7.6	0	0	34,621,586	26,681,827.5	0.25	1.84	0.00	0.00
2011	168	247	333	333	14.1	0	0	34,002,045	26,481,315.6	0.49	1.98	0.00	0.00
2012	83	113	137	137	6.3	0	0	33,404,942	25,759,262.9	0.25	1.65	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Eligible Members	Member- Years	New Users / 100K Eligible Members	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
<i>28 day episode extension</i>													
2006	1,383	2,742	3,295	3,295	204.1	8	13	14,802,561	8,849,042.9	9.34	2.38	39.20	63.71
2007	1,547	3,246	3,830	3,830	244.0	5	9	18,027,239	12,829,437.3	8.58	2.48	20.49	36.88
2008	156	219	225	225	16.8	0	0	34,328,645	21,392,117.6	0.45	1.44	0.00	0.00
2009	152	219	262	262	16.6	0	0	35,804,287	27,488,569.6	0.42	1.72	0.00	0.00
2010	86	129	158	158	9.7	0	0	34,621,586	26,681,827.5	0.25	1.84	0.00	0.00
2011	168	247	333	333	17.7	0	0	34,002,045	26,481,315.6	0.49	1.98	0.00	0.00
2012	83	113	137	137	7.8	0	0	33,404,942	25,759,262.9	0.25	1.65	0.00	0.00

Table 5: Summary of Incident Ig Use and Hemolysis in the MSDD between January 1, 2006 and December 31, 2012, by Ig Product, Episode Extension Period, and Pre-Index

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
Flebogamma										
<i>3 day episode extension</i>										
0	395	1,252	1,771	1,771	15.2	3	5	4.48	196.85	328.08
1	257	793	1,004	1,004	9.3	0	0	3.91	0.00	0.00
2	445	1,102	1,309	1,309	12.7	5	5	2.94	394.63	394.63
3-4	527	1,457	1,701	1,701	16.7	0	0	3.23	0.00	0.00
5-6	216	530	616	616	6.1	0	0	2.85	0.00	0.00
7+	162	338	455	455	4.1	1	1	2.81	246.91	246.91
unable to classify	426	708	884	884	8.3	0	0	2.08	0.00	0.00
<i>14 day episode extension</i>										
0	395	1,252	1,771	1,771	52.1	4	6	4.48	76.73	115.10
1	257	793	1,004	1,004	32.9	0	0	3.91	0.00	0.00
2	445	1,102	1,309	1,309	45.0	6	6	2.94	133.39	133.39
3-4	527	1,457	1,701	1,701	60.0	2	2	3.23	33.36	33.36
5-6	216	530	616	616	21.9	1	1	2.85	45.66	45.66
7+	162	338	455	455	14.1	1	1	2.81	71.12	71.12
unable to classify	426	708	884	884	29.4	0	0	2.08	0.00	0.00
<i>21 day episode extension</i>										
0	395	1,252	1,771	1,771	75.2	4	6	4.48	53.23	79.84
1	257	793	1,004	1,004	47.6	0	0	3.91	0.00	0.00
2	445	1,102	1,309	1,309	65.1	7	7	2.94	107.53	107.53
3-4	527	1,457	1,701	1,701	86.9	2	2	3.23	23.01	23.01
5-6	216	530	616	616	31.8	2	2	2.85	62.89	62.89
7+	162	338	455	455	20.3	1	1	2.81	49.38	49.38
unable to classify	426	708	884	884	42.4	0	0	2.08	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	395	1,252	1,771	1,771	95.7	4	6	4.48	41.79	62.68
1	257	793	1,004	1,004	60.7	0	0	3.91	0.00	0.00
2	445	1,102	1,309	1,309	83.7	7	8	2.94	83.66	95.61
3-4	527	1,457	1,701	1,701	111.9	4	4	3.23	35.76	35.76
5-6	216	530	616	616	40.9	2	2	2.85	48.89	48.89
7+	162	338	455	455	25.8	1	1	2.81	38.71	38.71
unable to classify	426	708	884	884	54.0	2	2	2.08	37.02	37.02
Gammagard Liquid										
3 day episode extension										
0	2,293	8,022	9,601	9,601	93.2	3	4	4.19	32.19	42.92
1	1,917	6,399	7,395	7,395	73.3	4	4	3.86	54.56	54.56
2	1,774	5,325	5,970	5,970	60.6	2	3	3.37	33.03	49.55
3-4	1,838	5,202	5,821	5,821	59.0	4	5	3.17	67.76	84.70
5-6	785	1,914	2,138	2,138	21.7	6	6	2.72	276.50	276.50
7+	463	1,125	1,262	1,262	12.8	0	0	2.73	0.00	0.00
unable to classify	2,301	4,189	5,028	5,028	48.9	5	9	2.19	102.19	183.94
14 day episode extension										
0	2,293	8,022	9,601	9,601	329.2	3	4	4.19	9.11	12.15
1	1,917	6,399	7,395	7,395	262.7	4	5	3.86	15.23	19.03
2	1,774	5,325	5,970	5,970	218.1	3	4	3.37	13.75	18.34
3-4	1,838	5,202	5,821	5,821	213.3	8	11	3.17	37.51	51.58
5-6	785	1,914	2,138	2,138	78.2	8	8	2.72	102.30	102.30
7+	463	1,125	1,262	1,262	45.8	1	1	2.73	21.86	21.86
unable to classify	2,301	4,189	5,028	5,028	172.1	8	17	2.19	46.50	98.81
21 day episode extension										
0	2,293	8,022	9,601	9,601	474.2	4	7	4.19	8.44	14.76
1	1,917	6,399	7,395	7,395	379.5	5	13	3.86	13.17	34.25
2	1,774	5,325	5,970	5,970	316.0	5	6	3.37	15.83	18.99
3-4	1,838	5,202	5,821	5,821	309.2	11	20	3.17	35.57	64.68
5-6	785	1,914	2,138	2,138	113.3	8	8	2.72	70.64	70.64
7+	463	1,125	1,262	1,262	66.1	2	3	2.73	30.24	45.37
unable to classify	2,301	4,189	5,028	5,028	248.4	8	21	2.19	32.21	84.55

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	2,293	8,022	9,601	9,601	603.3	4	7	4.19	6.63	11.60
1	1,917	6,399	7,395	7,395	481.1	7	21	3.86	14.55	43.65
2	1,774	5,325	5,970	5,970	404.0	5	6	3.37	12.38	14.85
3-4	1,838	5,202	5,821	5,821	395.0	16	31	3.17	40.51	78.49
5-6	785	1,914	2,138	2,138	144.6	9	9	2.72	62.22	62.22
7+	463	1,125	1,262	1,262	84.5	2	3	2.73	23.67	35.51
unable to classify	2,301	4,189	5,028	5,028	316.3	8	21	2.19	25.29	66.39
Gammalex										
3 day episode extension										
0	23	48	73	73	0.6	0	0	3.17	0.00	0.00
1	7	16	19	19	0.2	0	0	2.71	0.00	0.00
2	9	17	21	21	0.2	0	0	2.33	0.00	0.00
3-4	7	23	23	23	0.3	0	0	3.29	0.00	0.00
5-6	4	4	5	5	0.1	0	0	1.25	0.00	0.00
7+	2	4	7	7	0.1	0	0	3.50	0.00	0.00
unable to classify	4	8	8	8	0.1	0	0	2.00	0.00	0.00
14 day episode extension										
0	23	48	73	73	2.1	0	0	3.17	0.00	0.00
1	7	16	19	19	0.6	0	0	2.71	0.00	0.00
2	9	17	21	21	0.7	0	0	2.33	0.00	0.00
3-4	7	23	23	23	0.9	0	0	3.29	0.00	0.00
5-6	4	4	5	5	0.2	0	0	1.25	0.00	0.00
7+	2	4	7	7	0.2	0	0	3.50	0.00	0.00
unable to classify	4	8	8	8	0.3	0	0	2.00	0.00	0.00
21 day episode extension										
0	23	48	73	73	3.0	0	0	3.17	0.00	0.00
1	7	16	19	19	0.9	0	0	2.71	0.00	0.00
2	9	17	21	21	1.0	0	0	2.33	0.00	0.00
3-4	7	23	23	23	1.4	0	0	3.29	0.00	0.00
5-6	4	4	5	5	0.2	0	0	1.25	0.00	0.00
7+	2	4	7	7	0.3	0	0	3.50	0.00	0.00
unable to classify	4	8	8	8	0.5	0	0	2.00	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	23	48	73	73	3.8	0	0	3.17	0.00	0.00
1	7	16	19	19	1.1	0	0	2.71	0.00	0.00
2	9	17	21	21	1.3	0	0	2.33	0.00	0.00
3-4	7	23	23	23	1.8	0	0	3.29	0.00	0.00
5-6	4	4	5	5	0.3	0	0	1.25	0.00	0.00
7+	2	4	7	7	0.3	0	0	3.50	0.00	0.00
unable to classify	4	8	8	8	0.6	0	0	2.00	0.00	0.00
Gamunex										
3 day episode extension										
0	1,490	5,772	7,315	7,315	68.1	2	2	4.91	29.36	29.36
1	1,226	4,220	5,014	5,014	48.8	1	1	4.09	20.50	20.50
2	1,260	3,635	4,227	4,227	41.8	1	1	3.35	23.92	23.92
3-4	1,261	3,425	3,858	3,858	38.9	2	2	3.06	51.45	51.45
5-6	506	1,179	1,350	1,350	13.5	0	0	2.67	0.00	0.00
7+	337	835	958	958	9.5	0	0	2.84	0.00	0.00
unable to classify	1,562	2,824	3,351	3,351	32.7	1	1	2.15	30.62	30.62
14 day episode extension										
0	1,490	5,772	7,315	7,315	238.6	4	5	4.91	16.76	20.95
1	1,226	4,220	5,014	5,014	173.2	1	1	4.09	5.77	5.77
2	1,260	3,635	4,227	4,227	149.5	2	2	3.35	13.38	13.38
3-4	1,261	3,425	3,858	3,858	140.2	5	5	3.06	35.66	35.66
5-6	506	1,179	1,350	1,350	48.3	1	2	2.67	20.72	41.44
7+	337	835	958	958	34.3	0	0	2.84	0.00	0.00
unable to classify	1,562	2,824	3,351	3,351	115.8	2	5	2.15	17.28	43.20
21 day episode extension										
0	1,490	5,772	7,315	7,315	343.6	4	6	4.91	11.64	17.46
1	1,226	4,220	5,014	5,014	249.5	4	4	4.09	16.03	16.03
2	1,260	3,635	4,227	4,227	216.0	5	6	3.35	23.15	27.78
3-4	1,261	3,425	3,858	3,858	202.5	7	7	3.06	34.57	34.57
5-6	506	1,179	1,350	1,350	69.8	2	3	2.67	28.66	42.99
7+	337	835	958	958	49.5	0	0	2.84	0.00	0.00
unable to classify	1,562	2,824	3,351	3,351	166.6	3	10	2.15	18.01	60.03

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	1,490	5,772	7,315	7,315	436.4	4	7	4.91	9.17	16.04
1	1,226	4,220	5,014	5,014	315.9	5	5	4.09	15.83	15.83
2	1,260	3,635	4,227	4,227	275.4	5	7	3.35	18.16	25.42
3-4	1,261	3,425	3,858	3,858	258.4	9	10	3.06	34.84	38.71
5-6	506	1,179	1,350	1,350	89.3	3	6	2.67	33.59	67.18
7+	337	835	958	958	63.4	0	0	2.84	0.00	0.00
unable to classify	1,562	2,824	3,351	3,351	210.9	3	15	2.15	14.22	71.11
Octagam										
3 day episode extension										
0	485	1,533	1,802	1,802	17.8	1	1	3.72	56.24	56.24
1	391	1,156	1,355	1,355	13.3	0	0	3.47	0.00	0.00
2	415	1,195	1,360	1,360	13.7	1	2	3.28	73.21	146.41
3-4	420	1,124	1,278	1,278	12.9	2	6	3.04	155.04	465.12
5-6	203	431	477	477	4.9	1	1	2.35	204.92	204.92
7+	160	340	375	375	3.9	1	1	2.34	259.74	259.74
unable to classify	646	1,203	1,444	1,444	14.1	3	6	2.24	213.22	426.44
14 day episode extension										
0	485	1,533	1,802	1,802	63.0	2	2	3.72	31.77	31.77
1	391	1,156	1,355	1,355	47.7	1	1	3.47	20.96	20.96
2	415	1,195	1,360	1,360	49.2	2	3	3.28	40.64	60.96
3-4	420	1,124	1,278	1,278	46.4	2	6	3.04	43.08	129.25
5-6	203	431	477	477	17.6	2	2	2.35	113.90	113.90
7+	160	340	375	375	13.7	1	1	2.34	72.78	72.78
unable to classify	646	1,203	1,444	1,444	49.5	3	17	2.24	60.61	343.43
21 day episode extension										
0	485	1,533	1,802	1,802	91.0	2	2	3.72	21.98	21.98
1	391	1,156	1,355	1,355	69.1	1	1	3.47	14.47	14.47
2	415	1,195	1,360	1,360	71.4	2	3	3.28	28.02	42.02
3-4	420	1,124	1,278	1,278	67.4	3	7	3.04	44.54	103.92
5-6	203	431	477	477	25.4	2	3	2.35	78.74	118.11
7+	160	340	375	375	19.8	1	1	2.34	50.45	50.45
unable to classify	646	1,203	1,444	1,444	71.4	4	24	2.24	56.01	336.04

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	485	1,533	1,802	1,802	116.3	2	2	3.72	17.19	17.19
1	391	1,156	1,355	1,355	88.1	1	1	3.47	11.35	11.35
2	415	1,195	1,360	1,360	91.7	2	4	3.28	21.82	43.64
3-4	420	1,124	1,278	1,278	86.2	3	7	3.04	34.80	81.21
5-6	203	431	477	477	32.4	2	3	2.35	61.65	92.48
7+	160	340	375	375	25.4	1	1	2.34	39.37	39.37
unable to classify	646	1,203	1,444	1,444	91.3	4	28	2.24	43.82	306.75
Privigen										
3 day episode extension										
0	667	2,032	2,666	2,666	24.3	1	4	4.00	41.22	164.88
1	600	1,758	2,107	2,107	20.4	0	0	3.51	0.00	0.00
2	603	1,615	1,933	1,933	18.7	2	2	3.21	107.01	107.01
3-4	704	1,832	2,178	2,178	21.1	1	1	3.09	47.37	47.37
5-6	303	724	797	797	8.2	2	2	2.63	244.50	244.50
7+	204	452	533	533	5.2	0	0	2.61	0.00	0.00
unable to classify	626	1,081	1,319	1,319	12.5	4	5	2.11	318.98	398.72
14 day episode extension										
0	667	2,032	2,666	2,666	84.2	1	4	4.00	11.88	47.51
1	600	1,758	2,107	2,107	72.5	2	2	3.51	27.60	27.60
2	603	1,615	1,933	1,933	66.4	4	8	3.21	60.26	120.52
3-4	704	1,832	2,178	2,178	75.6	1	1	3.09	13.22	13.22
5-6	303	724	797	797	29.6	2	3	2.63	67.50	101.25
7+	204	452	533	533	18.5	0	0	2.61	0.00	0.00
unable to classify	626	1,081	1,319	1,319	44.2	4	5	2.11	90.58	113.22
21 day episode extension										
0	667	2,032	2,666	2,666	121.3	1	4	4.00	8.25	32.99
1	600	1,758	2,107	2,107	104.7	2	2	3.51	19.10	19.10
2	603	1,615	1,933	1,933	95.9	4	13	3.21	41.69	135.50
3-4	704	1,832	2,178	2,178	109.6	1	1	3.09	9.13	9.13
5-6	303	724	797	797	42.9	2	3	2.63	46.59	69.88
7+	204	452	533	533	26.5	0	0	2.61	0.00	0.00
unable to classify	626	1,081	1,319	1,319	63.7	4	5	2.11	62.83	78.54

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	667	2,032	2,666	2,666	154.4	1	4	4.00	6.48	25.91
1	600	1,758	2,107	2,107	133.0	3	3	3.51	22.56	22.56
2	603	1,615	1,933	1,933	122.5	4	17	3.21	32.66	138.82
3-4	704	1,832	2,178	2,178	140.2	3	3	3.09	21.41	21.41
5-6	303	724	797	797	54.9	2	3	2.63	36.40	54.61
7+	204	452	533	533	33.8	0	0	2.61	0.00	0.00
unable to classify	626	1,081	1,319	1,319	81.0	4	5	2.11	49.37	61.71
Lyophilized product IV										
3 day episode extension										
0	1,271	4,497	5,661	5,661	52.9	2	2	4.45	37.79	37.79
1	1,025	3,496	4,277	4,277	40.7	4	5	4.17	98.21	122.76
2	1,001	2,771	3,239	3,239	31.9	4	4	3.24	125.43	125.43
3-4	1,049	2,858	3,311	3,311	32.8	5	5	3.16	152.67	152.67
5-6	441	1,088	1,249	1,249	12.4	2	2	2.83	161.29	161.29
7+	328	836	932	932	9.4	4	4	2.84	425.53	425.53
unable to classify	2,031	3,682	4,389	4,389	42.6	2	3	2.16	46.96	70.44
14 day episode extension										
0	1,271	4,497	5,661	5,661	186.0	2	2	4.45	10.75	10.75
1	1,025	3,496	4,277	4,277	143.9	4	5	4.17	27.79	34.74
2	1,001	2,771	3,239	3,239	114.2	6	6	3.24	52.53	52.53
3-4	1,049	2,858	3,311	3,311	117.5	6	6	3.16	51.08	51.08
5-6	441	1,088	1,249	1,249	44.5	2	2	2.83	44.92	44.92
7+	328	836	932	932	33.9	5	7	2.84	147.41	206.37
unable to classify	2,031	3,682	4,389	4,389	151.5	6	7	2.16	39.62	46.22
21 day episode extension										
0	1,271	4,497	5,661	5,661	268.3	3	5	4.45	11.18	18.64
1	1,025	3,496	4,277	4,277	207.8	5	6	4.17	24.07	28.88
2	1,001	2,771	3,239	3,239	165.4	6	6	3.24	36.28	36.28
3-4	1,049	2,858	3,311	3,311	170.3	6	6	3.16	35.22	35.22
5-6	441	1,088	1,249	1,249	64.5	2	3	2.83	31.03	46.54
7+	328	836	932	932	49.1	5	8	2.84	101.94	163.10
unable to classify	2,031	3,682	4,389	4,389	218.6	6	7	2.16	27.45	32.03

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	1,271	4,497	5,661	5,661	341.5	3	6	4.45	8.79	17.57
1	1,025	3,496	4,277	4,277	264.2	5	6	4.17	18.93	22.71
2	1,001	2,771	3,239	3,239	211.5	7	9	3.24	33.09	42.55
3-4	1,049	2,858	3,311	3,311	218.5	7	7	3.16	32.03	32.03
5-6	441	1,088	1,249	1,249	82.6	2	3	2.83	24.22	36.33
7+	328	836	932	932	62.8	6	9	2.84	95.60	143.40
unable to classify	2,031	3,682	4,389	4,389	278.7	7	8	2.16	25.12	28.71
Non-lyophilized intramuscular route										
3 day episode extension										
0	3,590	4,561	4,591	4,591	50.1	1	1	1.28	19.96	19.96
1	832	1,337	1,348	1,348	14.7	0	0	1.62	0.00	0.00
2	348	566	573	573	6.2	0	0	1.65	0.00	0.00
3-4	219	345	348	348	3.8	0	0	1.59	0.00	0.00
5-6	93	137	144	144	1.5	0	0	1.55	0.00	0.00
7+	60	98	106	106	1.1	0	0	1.77	0.00	0.00
unable to classify	1,159	1,605	1,614	1,614	17.6	0	0	1.39	0.00	0.00
14 day episode extension										
0	3,590	4,561	4,591	4,591	185.9	1	1	1.28	5.38	5.38
1	832	1,337	1,348	1,348	54.4	0	0	1.62	0.00	0.00
2	348	566	573	573	22.9	0	0	1.65	0.00	0.00
3-4	219	345	348	348	13.8	0	0	1.59	0.00	0.00
5-6	93	137	144	144	5.6	0	0	1.55	0.00	0.00
7+	60	98	106	106	4.1	0	0	1.77	0.00	0.00
unable to classify	1,159	1,605	1,614	1,614	65.1	0	0	1.39	0.00	0.00
21 day episode extension										
0	3,590	4,561	4,591	4,591	270.6	1	1	1.28	3.70	3.70
1	832	1,337	1,348	1,348	78.8	0	0	1.62	0.00	0.00
2	348	566	573	573	33.1	0	0	1.65	0.00	0.00
3-4	219	345	348	348	19.9	0	0	1.59	0.00	0.00
5-6	93	137	144	144	8.0	0	0	1.55	0.00	0.00
7+	60	98	106	106	5.8	0	0	1.77	0.00	0.00
unable to classify	1,159	1,605	1,614	1,614	94.3	0	0	1.39	0.00	0.00

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	3,590	4,561	4,591	4,591	352.3	1	1	1.28	2.84	2.84
1	832	1,337	1,348	1,348	102.2	0	0	1.62	0.00	0.00
2	348	566	573	573	42.6	0	0	1.65	0.00	0.00
3-4	219	345	348	348	25.7	0	0	1.59	0.00	0.00
5-6	93	137	144	144	10.2	0	0	1.55	0.00	0.00
7+	60	98	106	106	7.5	0	0	1.77	0.00	0.00
unable to classify	1,159	1,605	1,614	1,614	122.4	0	0	1.39	0.00	0.00
Non-lyophilized unspecified route										
3 day episode extension										
0	2,793	3,552	3,596	3,596	38.8	29	38	1.29	746.65	978.37
1	1,082	1,351	1,375	1,375	14.7	19	23	1.27	1289.88	1561.44
2	987	1,189	1,223	1,223	12.9	26	29	1.24	2013.94	2246.32
3-4	1,008	1,180	1,207	1,207	12.8	27	31	1.20	2109.38	2421.88
5-6	523	584	592	592	6.4	11	11	1.13	1732.28	1732.28
7+	355	390	393	393	4.2	5	5	1.11	1179.25	1179.25
unable to classify	1,697	1,969	1,997	1,997	21.5	21	26	1.18	976.74	1209.30
14 day episode extension										
0	2,793	3,552	3,596	3,596	143.6	35	69	1.29	243.75	480.53
1	1,082	1,351	1,375	1,375	54.5	19	31	1.27	348.69	568.91
2	987	1,189	1,223	1,223	47.6	28	45	1.24	588.48	945.78
3-4	1,008	1,180	1,207	1,207	47.3	31	47	1.20	655.67	994.08
5-6	523	584	592	592	23.5	12	15	1.13	510.86	638.57
7+	355	390	393	393	15.8	6	10	1.11	380.71	634.52
unable to classify	1,697	1,969	1,997	1,997	79.6	21	35	1.18	263.95	439.92
21 day episode extension										
0	2,793	3,552	3,596	3,596	208.5	40	86	1.29	191.86	412.49
1	1,082	1,351	1,375	1,375	79.2	19	39	1.27	239.81	492.24
2	987	1,189	1,223	1,223	69.1	29	56	1.24	419.50	810.07
3-4	1,008	1,180	1,207	1,207	68.7	32	53	1.20	465.73	771.36
5-6	523	584	592	592	34.2	14	18	1.13	409.12	526.01
7+	355	390	393	393	23.0	6	13	1.11	261.10	565.71
unable to classify	1,697	1,969	1,997	1,997	115.3	22	40	1.18	190.81	346.92

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
28 day episode extension										
0	2,793	3,552	3,596	3,596	271.8	41	93	1.29	150.85	342.18
1	1,082	1,351	1,375	1,375	103.3	20	50	1.27	193.65	484.12
2	987	1,189	1,223	1,223	90.1	31	66	1.24	343.91	732.19
3-4	1,008	1,180	1,207	1,207	89.7	33	63	1.20	368.06	702.65
5-6	523	584	592	592	44.8	14	23	1.13	312.78	513.85
7+	355	390	393	393	30.1	6	14	1.11	199.07	464.50
unable to classify	1,697	1,969	1,997	1,997	149.8	23	42	1.18	153.50	280.30
Other IVIg, brand not specified										
3 day episode extension										
0	826	1,713	2,093	2,093	20.1	0	0	2.53	0.00	0.00
1	500	953	1,148	1,148	11.1	0	0	2.30	0.00	0.00
2	409	757	929	929	8.8	1	2	2.27	113.38	226.76
3-4	376	729	832	832	8.3	0	0	2.21	0.00	0.00
5-6	167	284	324	324	3.3	1	1	1.94	307.69	307.69
7+	99	178	194	194	2.0	0	0	1.96	0.00	0.00
unable to classify	1,286	2,301	2,720	2,720	26.6	2	3	2.12	75.19	112.78
14 day episode extension										
0	826	1,713	2,093	2,093	69.5	1	1	2.53	14.38	14.38
1	500	953	1,148	1,148	39.2	0	0	2.30	0.00	0.00
2	409	757	929	929	31.3	1	5	2.27	31.98	159.90
3-4	376	729	832	832	29.8	0	0	2.21	0.00	0.00
5-6	167	284	324	324	11.5	3	3	1.94	260.42	260.42
7+	99	178	194	194	7.1	0	0	1.96	0.00	0.00
unable to classify	1,286	2,301	2,720	2,720	93.9	4	6	2.12	42.61	63.91
21 day episode extension										
0	826	1,713	2,093	2,093	100.0	1	1	2.53	10.00	10.00
1	500	953	1,148	1,148	56.4	0	0	2.30	0.00	0.00
2	409	757	929	929	45.1	1	5	2.27	22.17	110.86
3-4	376	729	832	832	42.9	0	0	2.21	0.00	0.00
5-6	167	284	324	324	16.4	3	3	1.94	183.49	183.49
7+	99	178	194	194	10.1	0	0	1.96	0.00	0.00
unable to classify	1,286	2,301	2,720	2,720	135.2	5	10	2.12	36.99	73.99

	New Users	New Episodes	Dispensings	Days Supplied	Years at Risk	New Episodes w/ Events	Number of Events	Dispensings / User	New Episodes w/ Events / 1K Years at Risk	Total Number of Events / 1K Years at Risk
<i>28 day episode extension</i>										
0	826	1,713	2,093	2,093	127.7	1	1	2.53	7.83	7.83
1	500	953	1,148	1,148	71.4	0	0	2.30	0.00	0.00
2	409	757	929	929	57.6	1	5	2.27	17.36	86.82
3-4	376	729	832	832	54.8	0	0	2.21	0.00	0.00
5-6	167	284	324	324	20.7	3	3	1.94	144.86	144.86
7+	99	178	194	194	12.8	1	1	1.96	78.13	78.13
unable to classify	1,286	2,301	2,720	2,720	171.8	7	12	2.12	40.74	69.84

Appendix A. Code List for Ig Products

Ig Product	Code	Code Type
Gammaplex	J1557, C9270	HCPCS
Privigen	J1549, Q4097	HCPCS
Gamunex	J1561, Q4092	HCPCS
Octagam	J1568, Q4087	HCPCS
Gammagard Liquid	J1569, Q4088	HCPCS
Flebogamma	J1572, Q4091	HCPCS
Lyophilized product IV	J1566, Q9941, Q9942	HCPCS
Non-lyophilized intramuscular route	90281, J1460, J1470, J1480, J1490, J1500, J1510, J1520, J1530, J1540, J1550, J1560, P9014	CPT and HCPCS
Non-lyophilized unspecified route	90399, 99.14	CPT and ICD-9 Procedure
Other IVIg, brand not specified	J1563, J1564, J1567, J1599, Q9943, Q9944, S9545, 90283	HCPCS

Appendix B. Hemolysis Events

Description	Code	Code Type
Acquired hemolytic anemias	283*	ICD-9
ABO incompatibility reaction	999.6	ICD-9
Rh incompatibility reaction	999.7	ICD-9
Hemolytic transfusion reaction, incompatibility unspecified	999.83	ICD-9
Acute hemolytic transfusion reaction, incompatibility unspecified	999.84	ICD-9
Delayed hemolytic transfusion reaction, incompatibility unspecified	999.85	ICD-9